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Objective. To develop an evidence- based guideline on contraception, assisted reproductive technologies (ART), 
fertility preservation with gonadotoxic therapy, use of menopausal hormone replacement therapy (HRT), pregnancy 
assessment and management, and medication use in patients with rheumatic and musculoskeletal disease (RMD).
Methods. We conducted a systematic review of evidence relating to contraception, ART, fertility preservation, 
HRT, pregnancy and lactation, and medication use in RMD populations, using Grading of Recommendations Assess-
ment, Development and Evaluation methodology to rate the quality of evidence and a group consensus process to 
determine final recommendations and grade their strength (conditional or strong). Good practice statements were 
agreed upon when indirect evidence was sufficiently compelling that a formal vote was unnecessary.
Results. This American College of Rheumatology guideline provides 12 ungraded good practice statements and 
131 graded recommendations for reproductive health care in RMD patients. These recommendations are intended to 
guide care for all patients with RMD, except where indicated as being specific for patients with systemic lupus ery-
thematosus, those positive for antiphospholipid antibody, and/or those positive for anti- Ro/SSA and/or anti- La/SSB 
antibodies. Recommendations and good practice statements support several guiding principles: use of safe and 
effective contraception to prevent unplanned pregnancy, pre- pregnancy counseling to encourage conception dur-
ing periods of disease quiescence and while receiving pregnancy- compatible medications, and ongoing physician- 
patient discussion with obstetrics/gynecology collaboration for all reproductive health issues, given the overall low 
level of available evidence that relates specifically to RMD.
Guidelines and recommendations developed and/or endorsed by the American College of Rheumatology 
(ACR) are intended to provide guidance for patterns of practice and not to dictate the care of a particular 
patient. The ACR considers adherence to the recommendations within this guideline to be voluntary, with 
the ultimate determination regarding their application to be made by the clinician in light of each patient’s 
individual circumstances. Guidelines and recommendations are intended to promote beneficial or desirable 
outcomes, but cannot guarantee any specific outcome. Guidelines and recommendations developed and 
endorsed by the ACR are subject to periodic revision, as warranted by the evolution of medical knowledge, 
technology, and practice. ACR recommendations are not intended to dictate payment or insurance deci-
sions. These recommendations cannot adequately convey all uncertainties and nuances of patient care.
The American College of Rheumatology is an independent, professional, medical and scientific society that 
does not guarantee, warrant, or endorse any commercial product or service.
SAMMARITANO ET AL 462       |
Conclusion. This guideline provides evidence- based recommendations developed and reviewed by panels of 
experts and RMD patients. Many recommendations are conditional, reflecting a lack of data or low- level data. We 
intend that this guideline be used to inform a shared decision- making process between patients and their physicians 
on issues related to reproductive health that incorporates patients’ values, preferences, and comorbidities.
INTRODUCTION
The management of reproductive health issues in patients 
with rheumatic and musculoskeletal diseases (RMD) differs from 
that in healthy persons. As a result, rheumatologists and other 
clinicians caring for these patients must often discuss with and 
counsel their patients about contraception, pregnancy and lac-
tation (including medications), assisted reproductive technology 
(ART), fertility preservation, and hormone replacement therapy 
(HRT), and they must collaborate with specialists in the fields of 
obstetrics- gynecology, maternal- fetal medicine, and reproduc-
tive endocrinology and infertility.
Pregnancy in women with RMD may lead to serious maternal 
or fetal adverse outcomes; accordingly, contraception, tailored to 
the individual patient with emphasis on safety and efficacy, should 
be discussed and encouraged. Because risk for pregnancy com-
plications depends on diagnosis, disease activity and damage, 
medications, and the presence of anti- Ro/SSA, anti- La/SSB, and 
antiphospholipid (aPL) antibodies, pre- pregnancy assessment is 
critical to informing pregnancy management, therapy, and out-
comes. The ability to become pregnant may itself be an inde-
pendent concern for some patients, so minimizing risk of gonadal 
insufficiency is important. RMD patients with subfertility value 
advice from their rheumatologists about oocyte preservation and 
in vitro fertilization (IVF).
It is difficult to avoid use of medication during pregnancy 
in patients with RMD. Not all medications are safe for pre- 
conception use by men and women or during pregnancy and 
lactation, but uncontrolled systemic inflammatory disease is 
itself associated with poor pregnancy outcomes (1–6). In addi-
tion, patients are vulnerable to disease flare postpartum (7,8), 
but the American Academy of Pediatrics recommends that 
infants be exclusively breastfed for 6 months (9). In many cases 
medication safety is uncertain because most data are derived 
from case reports, small series, and observational studies; 
direct data from randomized controlled trials are scarce. As a 
result, identifying the appropriate screening and management 
(including medication use) for RMD patients is challenging for 
clinicians.
Given the primary goal of providing recommendations for care 
of all adult RMD patients throughout the reproductive lifespan, the 
scope of this guideline is broad. There has been little attention 
to aspects of reproductive health care other than pregnancy in 
patients with RMD, and the American College of Rheumatology 
(ACR) recognizes the imperative for guidance in reproductive 
health issues for these patients.
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METHODS
These recommendations follow the ACR guideline develop-
ment process, using a systematic literature review and Grading 
of Recommendations Assessment, Development and Evalua-
tion methodology (for details, see Supplementary Appendices 1, 
2, and 3, available on the Arthritis Care & Research web site at 
http://onlinelibrary.wiley.com/doi/10.1002/acr.24130/abstract). 
When no direct data on RMD patients were available from the 
systematic literature review, discussion and voting were supple-
mented with indirect data collected in additional, less formal litera-
ture reviews (Supplementary Appendix 4, http://onlin elibr ary.wiley.
com/doi/10.1002/acr.24130/ abstract) performed by Core Team 
members (Supplementary Appendix 5, http://onlin elibr ary.wiley.
com/doi/10.1002/acr.24130/ abstract); these data were not part 
of the systematic literature review and are listed as “not graded” 
in evidence tables. Results of the systematic literature review were 
compiled in an Evidence Report (Supplementary Appendix 6, 
http://onlin elibr ary.wiley.com/doi/10.1002/acr.24130/abstract).
A strong recommendation suggests that most informed 
patients would choose the recommended management. While 
usually reflecting a higher level of evidence, it may also reflect the 
severity of a potential negative outcome. A conditional recommen-
dation suggests that choice will vary with individual values and 
preferences. Conditional recommendations generally reflect a lack 
of data, limited data, or conflicting data that lead to uncertainty. 
Finally, good practice statements are those for which indirect evi-
dence is sufficiently compelling that a formal vote is unnecessary. 
They are presented as “suggestions” rather than formal recom-
mendations. Recommendation numbers are denoted in Supple-
mentary Appendix 7 (http://onlin elibr ary.wiley.com/doi/10.1002/
acr.24130/abstract.) as numbers in parentheses, allowing for 
cross- referencing of recommendations with tables/appendices, 
and referencing the order in the original list (i.e., may not be con-
secutive in the supplementary appendix.)
RESULTS/RECOMMENDATIONS
The detailed tables of recommendations appear in Supple-
mentary Appendix 7 (available on the Arthritis Care & Research 
web site at http://onlinelibrary.wiley.com/doi/10.1002/acr.24130/
abstract). Concise recommendations within this appendix and 
throughout the article are grouped into categories of  contraception, 
Figure 1. Recommendations and good practice statements (GPS) for use of contraception in women with rheumatic and musculoskeletal 
disease (RMD). aPL = antiphospholipid antibody (persistent moderate [Mod]–to- high–titer anticardiolipin or anti–β2- glycoprotein I antibody or 
persistent positive lupus anticoagulant); IUDs = intrauterine devices (copper or progestin); SLE = systemic lupus erythematosus; DMPA = depot 
medroxyprogesterone acetate.







IUDs*, progestin implant, 
combined estrogen and
progesterone pill, progestin-
only pill (less effective), 
transdermal patch, vaginal ring, 
or DMPA [1]
IUDs*, progestin implant, 
combined estrogen and
progesterone pill, progestin-
only pill (less effective), vaginal 
ring, or DMPA [2]
Assess aPL status
IUDs or progestin implant 
preferred over other hormonal 
contraceptives [1A]
IUDs* (preferred) or progestin-
only pill (less effective) [4]
Discuss contraception and pregnancy planning at initial or early visit with women of reproductive age and counsel regarding 
efficacy and safety [GPS]. Recommend barrier methods if more effective methods are contraindicated [GPS]. Recommend 






Bracketed #’s refer to Recommendation 
# (See Appendix 7)
IUDs*, progestin implant, 
DMPA, or progestin-only pill 
over combined estrogen-
progestin contraceptives [2C]
IUDs or progestin implant 
preferred over other hormonal 
contraceptives[2A]
AVOID estrogen patch [2B]
* Recommendation for IUD use includes
women receiving immunosuppression 
therapy [7]
AVOID estrogen patch [2B]
SPECIAL CIRCUMSTANCES:
Use of mycophenolate 
medications requires an IUD or 
the combination of two other 
forms of contraception [11].
Avoid DMPA in patients at risk 
for osteoporosis [10]
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ART, fertility preservation with gonadotoxic therapy, use of men-
opausal HRT, pregnancy assessment and management, and 
medication use (compatibilities for paternal, maternal, and breast-
feeding use are reported).
Most recommendations are general; when relevant, RMDs 
are specifically identified, most often for systemic lupus erythema-
tosus (SLE) or according to presence of specific autoantibodies 
(aPL and anti- Ro/SSA and anti- La/SSB antibodies). In general, 
testing for aPL should be performed in patients with SLE or SLE- 
like disease and in patients with suggestive histories or physical 
findings; whether to check these antibodies in other RMD patients 
with a lower likelihood of positive results should be decided by 
physician- patient discussion. The presence of aPL modifies the 
recommendations in many circumstances, and therefore is con-
sidered separately. “Positive aPL” throughout this guideline refers 
to laboratory criteria only (10): persistent (2 positive test results at 
least 12 weeks apart) moderate- high–titer anticardiolipin antibody 
(aCL) (≥40 units or ≥99th percentile), moderate- high–titer anti– 
β2- glycoprotein I (anti- β2GPI) (≥40 units or ≥99th percentile), or 
positive lupus anticoagulant (LAC).
Detailed definitions of aPL and antiphospholipid syndrome 
(APS) are presented in Supplementary Appendix 8 (available on 
the Arthritis Care & Research web site at http://onlinelibrary.wiley.
com/doi/10.1002/acr.24130/abstract). Briefly, included within the 
positive aPL group are patients with asymptomatic aPL who have 
no history of thrombosis or pregnancy morbidity (i.e., meet labora-
tory but not clinical APS criteria), patients with obstetric APS (OB 
APS), and patients with thrombotic APS. OB APS refers to patients 
who meet laboratory criteria for APS and have  experienced prior 
pregnancy complications consistent with APS (with other causes 
ruled out). These include 3 consecutive losses prior to 10 weeks’ 
gestation, a fetal loss at or after 10 weeks’ gestation, or delivery 
at <34 weeks due to preeclampsia, intrauterine growth restric-
tion, or fetal distress. Thrombotic APS refers to patients who meet 
laboratory criteria for APS and have experienced a prior throm-
botic event (arterial or venous), regardless of whether they have 
had obstetric complications. The aPL definitions in the guideline 
include both patients with and patients without other underlying 
autoimmune disease, unless specifically stated.
Patients with lower- titer aCL and/or anti- β2GPI (or non- 
criteria aPL) who do not meet laboratory classification criteria 
may still have some degree of risk that is difficult to quantify. Rec-
ommendations for these patients are not offered in this guide-
line; decisions regarding therapy rest on discussion between the 
patient and the physician, taking into account additional relevant 
risk factors.
Contraception
Supplementary Appendix 7, Table A (on the Arthritis Care & 
Research web site at http://onlinelibrary.wiley.com/doi/10.1002/
acr.24130/abstract) presents formal recommendations regarding 
contraception; strength of evidence and justifications for strong 
and conditional recommendations are shown in Supplementary 
Appendix 9 (http://onlin elibr ary.wiley.com/doi/10.1002/acr.24130/ 
 abstract). Figure  1 details the contraception decision- making 
Table 1. Safety and efficacy of various contraceptive methods in women with RMD*
Method Safety in women with RMD
1- year failure 
rate, %†
Highly effective (LARC)
Copper IUD Safe in all women with RMD; may increase menstrual bleeding <1
Progestin IUD Safe in all women with RMD; may decrease menstrual bleeding <1
Progestin implant Limited data, but likely safe in all women with RMD <1
Effective
Progestin- only pill (daily) Safe in all women with RMD; higher rate of breakthrough bleeding than with 
combined contraceptives; must take same time every day for efficacy
5–8
DMPA (IM injection every 12 weeks) Safe in most women with RMD; exceptions: positive aPL, at high risk for OP 3
Combined estrogen and 
progesterone pill (daily)
Safe in most women with RMD; exceptions: positive aPL, very active SLE 5–8
Transdermal patch (weekly) Safe in most women with RMD; exceptions: positive aPL, SLE; serum 
estrogen levels higher than with pill or vaginal ring
5–8
Vaginal ring (monthly) Safe in most women with RMD; exceptions: positive aPL, very active SLE 5–8
Less effective
Diaphragm Safe in all women with RMD 12
Condom Safe in all women with RMD; only form to prevent STD 18
Fertility awareness–based methods‡ Safe in all women with RMD; limited efficacy, especially if menses are 
irregular
24
Spermicide Safe in all women with RMD; use with condoms or diaphragm to improve 
efficacy
28
* RMD = rheumatic and musculoskeletal disease; LARC = long- acting reversible contraception; IUD = intrauterine device; DMPA = 
depot medroxyprogesterone acetate; IM = intramuscular; aPL = antiphospholipid antibody; OP = osteoporosis; SLE = systemic lupus 
erythematosus; STD = sexually transmitted disease. 
† Percent of women who will become pregnant within the first year of typical use. 
‡ Methods based on the timing of the menstrual cycle. 
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 process, and Table 1 provides efficacy data and comments on 
available contraceptives.
RMD patients typically underutilize effective contraception 
(11–13). The most important reason for effective contraception 
in women with RMD is to avoid risks of unplanned pregnancy, 
which include worsening disease activity that may threaten 
maternal organ function or life, adverse pregnancy outcomes 
(pregnancy loss, severe prematurity, and growth restriction), 
and teratogenesis. Members of a 1- day patient focus group, 
convened as part of the guideline process, emphasized their 
desire that clinicians caring for patients with RMD routinely dis-
cuss family planning, as they view their rheumatologists as “the 
doctors who know them and their medications best.” We sug-
gest that rheumatologists treating reproductive- age women with 
RMD discuss contraception and pregnancy plans at an initial 
or early visit and periodically thereafter, and always when initiat-
ing treatment with potentially teratogenic medications. One Key 
Question (www.power todec ide.org) has been suggested in the 
literature as a simple way of addressing the issue of family plan-
ning with patients: “Would you like to become pregnant in the 
next year?” (14). In whatever way one chooses to discuss this 
topic, counseling regarding contraception should include issues 
of efficacy and safety, with consideration of individual values and 
preferences.
Effectiveness of reversible forms of contraception varies. 
For long- acting reversible contraceptives (copper or progestin 
intrauterine devices [IUDs]) and subdermal progestin implants), 
ideal use and “real- world” use effectiveness are similar, with 
pregnancy rates of <1% per year (“highly effective”). Combined 
estrogen- progestin methods, depot medroxyprogesterone ace-
tate (DMPA) injections, and progestin- only pills yield pregnancy 
rates of 3–8% per year (“effective”) (15,16). Condoms, fertility- 
based methods (e.g., “rhythm”), and spermicide are less effec-
tive and yield pregnancy rates of 18–28% per year (17). Barrier 
methods confer some protection against sexually transmitted 
diseases.
While long- acting reversible contraceptives are encour-
aged as first- line contraceptives for all appropriate candidates, 
including nulliparous women and adolescents (17), lack of data 
specific to RMD and variability in clinical situations, values, and 
preferences may affect a patient’s choice. Clinical factors that 
affect appropriateness of various contraceptive methods include 
diagnosis and activity of SLE, presence of aPL, osteoporo-
sis, and some potentially interacting medications (see Special 
RMD Situations below and Supplementary Appendix 10, on 
the Arthritis Care & Research web site at http://onlinelibrary.
wiley.com/doi/10.1002/acr.24130/abstract). “Hormonal con-
traceptives” refers to any contraception containing a hormone, 
including estrogen- progestin contraceptives and progestin- only 
contraceptives. The term “fertile women” refers to women of 
reproductive age who do not have documented menopause, 
hysterectomy, or permanent sterilization (i.e., women who may 
become pregnant).
In fertile women with RMD who have neither SLE nor 
positive aPL, we strongly recommend use of effective con-
traceptives (i.e., hormonal contraceptives or IUDs) over 
less effective options or no contraception; among effective 
methods, we conditionally recommend the highly effective 
IUDs or subdermal progestin implant (long-acting revers-
ible contraceptives) because they have the lowest failure 
rates.
We strongly recommend discussing use of emergency 
contraception with all patients, including those with SLE 
or positive aPL, because risks of emergency contraception 
are low compared to those of unplanned pregnancy.
Levonorgestrel, the over- the- counter option, is widely avail-
able and has no medical contraindications to use, including 
thrombophilia (18).
SLE patients. Controlled studies of estrogen- progestin 
contraceptives in SLE have enrolled only women with stable, 
low disease activity; they specifically excluded those with high 
disease activity and history of thrombosis (19,20). Prospec-
tive studies (evidence level moderate) in patients with stable 
SLE showed no increased risk of flare related to estrogen- 
progestin pills (19,20), and there are no data suggesting 
increased SLE flare risk with progestin- only pills or copper 
IUDs (20,21).
In SLE patients with stable or low disease activity who 
are not positive for aPL, we strongly recommend use of 
effective contraceptives (i.e., hormonal contraceptives or 
IUDs) over less effective options or no contraception, and 
we conditionally recommend the highly effective IUDs or 
subdermal progestin implant because they have the low-
est failure rates.
We conditionally recommend against use of the trans-
dermal estrogen-progestin patch in patients with SLE.
Although not directly studied in SLE patients, the transder-
mal estrogen- progestin patch results in greater estrogen expo-
sure than do oral or transvaginal methods (22,23), raising concern 
regarding potential increased risk of flare or thrombosis.
We strongly recommend progestin-only or IUD contra-
ceptives over combined estrogen-progestin contraception 
in SLE patients with moderate or severe disease activity, 
including nephritis, because estrogen-containing contra-
ceptives have not been studied in SLE patients with mod-
erate or severe disease activity.
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Antiphospholipid antibody–positive patients. Pres-
ence of aPL, with or without history of clinical complications, is a 
contraindication to use of estrogen-containing contraceptives due 
the potential further increase in thrombosis risk.
We strongly recommend against combined estro-
gen-progestin contraceptives in women with positive aPL 
because estrogen increases risk of thromboembolism.
We strongly recommend IUDs (levonorgestrel or 
copper) or the progestin-only pill in women with positive 
aPL.
In aPL- positive patients, we do not recommend DMPA due 
to concern regarding thrombogenicity. We do not comment on 
the relatively new progestin implant due to lack of data.
The risk of venous thromboembolism (VTE) in healthy 
women taking combined estrogen- progestin contraceptives is 
36 times higher than the baseline annual risk of 1/10,000 women 
(24). Although whether there is any increase in thrombosis risk 
with progestin- only contraception is debated, progestin- only 
methods are widely accepted as a lower- risk option in patients 
for whom estrogens are contraindicated but who still need 
effective contraception (18,25,26). The specific progestin and 
its serum level affect thrombosis risk: in healthy women tak-
ing estrogen- progestin contraceptive pills that vary progestin 
type but not estrogen, VTE risk odds ratios range from 2.2 to 
6.6 (24). However, VTE risk in healthy women using either the 
progestin- only pill or the progestin IUD is not increased, with 
relative risks (RRs) of 0.90 (95% confidence interval [95% CI] 
0.57–1.45) and 0.61 (95% CI 0.24–1.53), respectively (27). Fur-
thermore, thrombosis frequency does not increase when pro-
gestin (levonorgestrel) IUDs are used in non- RMD patients with 
increased (non–aPL- associated) thrombosis risk (27–29). VTE 
data on the newer progestin (etonogestrel) subdermal implant 
are inadequate to permit recommendations (the prior progestin 
implant containing levonorgestrel is no longer available in the 
US). Very limited data on non- RMD patients suggest that inject-
able DMPA imparts a higher VTE risk than do other progestin- 
only contraceptives (RR 2.67 [95% CI1.29–5.53]), similar to 
that with oral estrogen- progestin contraceptives (27). For this 
reason, we do not include DMPA among the progestin contra-
ceptives recommended for use in patients with positive aPL.
The copper IUD is a highly effective alternative that does not 
increase risk of VTE, but it may increase menstrual bleeding and 
cramping for several months after insertion. Progestin IUDs may 
decrease these symptoms (30), a potential benefit for patients 
receiving anticoagulation therapy.
We suggest the progestin- only pill (which is an effective, 
but not highly effective, contraceptive) as a low- risk alterna-
tive for patients who are unable or unwilling to use an IUD. 
The lack of data specific to aPL- positive patients using the 
progestin- only pill or IUD must be weighed against the risk of 
pregnancy- related VTE in the general population, which is >10 
times that seen with estrogen- progestin contraceptive use. 
Pregnancy- related thrombosis risk in aPL- positive patients is 
not well quantified, but VTE risk is 197/10,000 women- years 
for pregnant patients with a single prothrombotic mutation and 
776/10,000 women- years (31) if there are multiple prothrom-
botic mutations.
Other special RMD situations. Factors other than diag-
nosis of SLE or presence of aPL may influence the choice of 
contraception in women with RMD. These include use of medica-
tions and presence or risk of osteoporosis. Immunosuppressive 
therapy does not preclude use of any contraceptive method, but 
there is concern that mycophenolate-containing medications may 
interfere with hormonal contraceptive efficacy.
Since IUDs are the most effective contraceptive 
options, we strongly recommend the IUD (copper or pro-
gestin) for women with RMD who are receiving immuno-
suppressive therapy, despite hypothetical infection risk.
IUD- associated infection risk in RMD patients receiving 
immunosuppressive therapy has not been specifically studied, 
but studies in women with HIV show no increase (32), and IUDs 
are recommended for all solid organ transplant patients, including 
adolescents (33,34). In one arm of an SLE contraceptive trial a 
copper IUD was used; although the number of patients  receiving 
immunosuppressive agents was not reported, there were no 
cases of pelvic inflammatory disease (20).
In women with RMD who are at increased risk for oste-
oporosis from glucocorticoid use or underlying disease, we 
conditionally recommend against using DMPA as a long-
term contraceptive because data suggest that bone min-
eral density declines by up to 7.5% over 2 years of use in a 
healthy population (35).
Although there are no published data suggesting increased 
fracture risk, the American College of Obstetricians and Gynecol-
ogists recommends caution regarding DMPA use in women with 
or at increased risk for osteoporosis (17).
We conditionally recommend that women with RMD 
taking mycophenolate mofetil/mycophenolic acid (MMF) 
use an IUD alone or 2 other methods of contraception 
together, because MMF may reduce serum estrogen and 
progesterone levels (in turn reducing the efficacy of oral 
contraceptives).
The Mycophenolate Risk Evaluation and Mitigation Strategy 
program suggests use of an IUD alone (copper or progestin is not 
specified), or an estrogen- progestin contraceptive or the progestin 
implant together with a barrier contraceptive (36). It is not known 
whether these medications reduce efficacy of progestin IUDs, 
which contain varying amounts of hormone and have a largely 
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intrauterine effect. Other recommendations vary: while the package 
insert states that MMF may reduce effectiveness of oral contracep-
tives and use of additional barrier contraceptive methods is rec-
ommended (37), the European Medicine Agency recently updated 
recommendations regarding use of contraception for women tak-
ing MMF to state that “two forms of contraception are preferred but 
no longer mandatory”(38). Voting Panel members disagreed on the 
need to use additional contraceptive measures. As befits a condi-
tional recommendation, clinicians should be aware of and discuss 
this hypothetical risk with their patients.
Assisted reproductive technology
Supplementary Appendix 7, Table B (http://onlin elibr ary.
wiley.com/doi/10.1002/acr.24130/ abstract) presents the ART 
recommendations with strength of supporting evidence; detailed 
justifications for strong and conditional recommendations are 
shown in Supplementary Appendix 9 (http://onlin elibr ary.wiley.
com/doi/10.1002/acr.24130/ abstract). Figure  2 details the ART 
decision- making process.
While fertility is typically normal in women with RMD 
(who have not been treated with cyclophosphamide [CYC]), it 
decreases with age, and ART may be needed by some RMD 
patients. ART techniques include ovarian stimulation, which ele-
vates estrogen levels, IVF, and embryo transfer. Ovarian stimula-
tion cycles for IVF generally require more aggressive stimulation 
than do those for intrauterine insemination; they involve surgical 
extraction of oocytes and IVF, followed by embryo transfer. Fro-
zen embryo transfer does not usually require ovarian stimulation.
As is the case with any underlying significant medical disease, 
women undertaking ovarian stimulation must be cleared medically 
by the appropriate specialist. Similarly, women with APS, throm-
botic or otherwise, should be cleared medically by their rheuma-
tologist. The rheumatologist should consult with the reproductive 
endocrinology and infertility specialist regarding adjustments to 
the ovarian stimulation protocol in order to minimize the risk to the 
patient. Women with these underlying conditions who undergo 
fertility therapy should do so only in centers where the appropriate 
expertise is readily available.
We strongly recommend proceeding with ART if 
needed in women with uncomplicated RMD who are receiv-
ing pregnancy-compatible medications, whose disease is 
stable/quiescent, and who are negative for aPL.
Compared to the benefit of a successful pregnancy, the 
risk of ART for subfertile patients with RMD is low;  nonetheless, 
Figure 2. Recommendations for use of assisted reproductive technology (ART) in women with rheumatic and musculoskeletal disease (RMD). 
CYC = cyclophosphamide; aPL = antiphospholipid antibody (persistent moderate- to- high–titer anticardiolipin or anti–β2- glycoprotein I antibody 
or persistent positive lupus anticoagulant); APS = antiphospholipid syndrome (obstetric and/or thrombotic); obstetric APS (OB APS) = patients 
meeting laboratory criteria for APS and having prior consistent pregnancy complications (≥3 consecutive losses prior to 10 weeks’ gestation, 
fetal loss at or after 10 weeks’ gestation, or delivery at <34 weeks due to preeclampsia, intrauterine growth restriction, or fetal distress) and with 
no history of thrombosis; thrombotic APS = patients meeting laboratory criteria for APS and having a prior thrombotic event (arterial or venous), 
regardless of whether they have had obstetric complications; LMWH = low molecular weight heparin; UH = unfractionated heparin.
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risks associated with ART, especially thrombosis and lupus 
flare (39,40), should be discussed with patients. The level 
of evidence specific to RMD patients is very low (41,42), but 
evidence supports the safety of ART in a general population 
(43,44).
SLE patients. Data on IVF cycles in RMD patients are lim-
ited; however, the intended outcome of IVF, pregnancy, may be 
adversely affected by the presence of active RMD. In addition, 
there is concern that flare in SLE patients might be worsened in 
the setting of elevated estrogen levels.
We strongly recommend deferring ART procedures 
in patients with any RMD while disease is moderately or 
severely active; this recommendation is based on extrap-
olated evidence that RMD disease activity increases preg-
nancy risks.
For pregnancy planning, 6 months of stable inactive or low- 
level disease is most often suggested, but individual clinical fac-
tors may influence this decision. In patients with SLE, there is 
theoretical concern that ovarian stimulation with elevated estrogen 
levels may worsen active disease.
We conditionally recommend against an empiric 
dosage increase of prednisone during ART procedures 
in patients with SLE; instead, we suggest monitoring the 
patient carefully and treating for flare if it occurs.
No studies have evaluated prescription of prophylactic pred-
nisone to prevent SLE flare during ART.
Antiphospholipid antibody–positive patients. Patients 
who are positive for aPL are at increased risk for thrombosis. 
Most reports of aPL-positive patients undergoing IVF describe 
the use of empiric prophylactic anticoagulation due to concern 
regarding further increased risk of potentially life-threatening 
thrombosis from elevated estrogen levels during ovarian 
 stimulation.
In subfertile patients with RMD who desire preg-
nancy, have stable/quiescent disease, and have asymp-
tomatic positive aPL, OB APS, or treated thrombotic APS, 
we conditionally recommend ART with anticoagulation, as 
described below.
We conditionally recommend prophylactic anticoagu-
lation therapy with heparin or low molecular weight heparin 
in asymptomatic aPL-positive patients during ART proce-
dures (41,42).
The increased risk of organ- or life- threatening thrombosis 
due to high estrogen levels greatly outweighs the low risk of bleed-
ing or other complications of unfractionated heparin or low molec-
ular weight heparin (LMWH).
We strongly recommend prophylactic anticoagulation 
with heparin or LMWH in women with OB APS, and we 
strongly recommend therapeutic anticoagulation in women 
with thrombotic APS, during ART procedures.
The strength of these recommendations rests on the sever-
ity of the risk of organ- or life- threatening thrombosis during 
ovarian stimulation. An added risk for thrombosis is ovarian 
hyperstimulation syndrome, an important, uncommon complica-
tion consisting of capillary leak syndrome (with pleural effusion 
and ascites) and, in severe cases, arterial and venous throm-
bosis and renal failure (43). Underlying thrombophilia increases 
the risk of severe ovarian hyperstimulation syndrome (44). While 
there are few data to guide prophylactic anticoagulation in aPL- 
positive patients, thromboprophylaxis is recommended to pre-
vent thrombotic complications of moderate- to- severe ovarian 
hyperstimulation syndrome, as it is for patients with known inher-
ited or acquired thrombophilia (45,46). Reports of thrombosis in 
aPL- positive patients undergoing IVF are uncommon, but most 
reported patients received empiric anticoagulation (41,42). In a 
recent series, 2 of 4 reported thromboses occurred in women 
who, on their own decision, discontinued LMWH after oocyte 
retrieval (41).
LMWH is used most commonly. Prophylactic dosing of 
enoxaparin is usually 40 mg daily, started at the beginning of 
ovarian stimulation, withheld 24–36 hours prior to oocyte retrieval, 
and resumed following retrieval. Optimal duration of prophylactic 
LMWH for asymptomatic aPL- positive patients undergoing ovar-
ian stimulation has not been studied; this is a decision best made 
in consultation with the reproductive endocrinology and infertility 
specialist. The treatment is often continued until estrogen levels 
return to near- physiologic levels if no pregnancy occurs. Patients 
with OB APS will continue therapy throughout pregnancy. Aspirin 
is not commonly used prior to oocyte retrieval (it will be started 
after retrieval if indicated) given concern that its prolonged action 
may increase bleeding risk at the time of the retrieval. Patients 
receiving regular anticoagulation therapy with vitamin K antag-
onists for thrombotic APS should transition to therapeutic- dose 
LMWH for ART (usually enoxaparin 1 mg/kg subcutaneously 
every 12 hours), with this treatment withheld for retrieval and 
resumed subsequently, to continue throughout pregnancy. Since 
ovarian stimulation protocols vary, discussion with the reproduc-
tive endocrinology and infertility specialist is appropriate. In addi-
tion to anticoagulation, patients at risk for thrombosis or ovarian 
hyperstimulation syndrome may benefit from ovarian stimulation 
protocols that yield lower peak serum estrogen levels, such as 
those incorporating aromatase inhibitors (47).
Embryo and oocyte cryopreservation. Embryo and 
oocyte cryopreservation are good options to preserve fertility in 
patients whose condition is stable enough for them to undergo ovar-
ian stimulation but who are either not able or not ready to pursue 
pregnancy at the time of stimulation. A carefully monitored ovarian 
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stimulation/IVF cycle followed by embryo transfer to a surrogate is an 
option, if available, for patients with severe disease- related damage 
who desire a biologic child and are able to undergo ovarian stimula-
tion and oocyte retrieval, but cannot safely undergo pregnancy.
We strongly recommend continuation of necessary 
immunosuppressive and/or biologic therapies (except 
CYC, which directly impacts maturing follicles) in treated 
patients whose condition is stable, when the purpose 
of ovarian stimulation is oocyte retrieval for oocyte or 
embryo cryopreservation.
This includes continuation of mycophenolate or methotrex-
ate (MTX). There is an anticipated risk of uncontrolled disease from 
withdrawal of effective medication. However, there are no published 
data that directly address oocyte retrieval during treatment with most 
immunosuppressive or biologic therapies other than CYC.
Fertility preservation with cyclophosphamide
Supplementary Appendix 7, Table C (on the Arthritis Care & 
Research web site at http://onlinelibrary.wiley.com/doi/10.1002/
acr.24130/abstract) presents the formal  recommendations 
regarding fertility preservation with CYC treatment and strength 
of supporting evidence. Detailed justifications for strong and 
 conditional recommendations are shown in  Supplementary 
Appendix 9 (http://onlin elibr ary.wiley.com/doi/10.1002/acr.24130/ 
 abstract).
Fertility preservation in women with RMD treated 
with CYC. Although CYC is used less frequently than in the past 
due to availability of alternative treatments, it remains a mainstay 
of therapy for severe or life-threatening RMD. Ovarian insufficiency 
is a potential long-term complication of monthly intravenous CYC 
therapy. Hormonal co-therapy during the course of CYC is sug-
gested to reduce risk of ovarian insufficiency.
To prevent inducing primary ovarian insufficiency in 
premenopausal women with RMD receiving monthly intra-
venous CYC, we conditionally recommend monthly gonad-
otropin-releasing hormone agonist co-therapy.
Ovarian insufficiency risk with CYC treatment depends on 
patient age and cumulative monthly CYC dose (48); measures 
of ovarian function remained stable during treatment accord-
ing to the Euro- Lupus protocol (49). The recommendation of 
gonadotropin- releasing hormone agonist therapy for ovarian 
protection during monthly CYC therapy is based on evidence 
supporting benefit in early breast cancer (50,51); evidence more 
specific to RMD patients is less robust but positive, with lim-
ited clinical trials of gonadotropin- releasing hormone agonist 
(usually leuprolide acetate) that included patients with SLE and 
other RMD populations and used a number of different outcome 
measures (52–56).
Thus far, studies have addressed gonadotropin- releasing 
hormone agonist co- therapy only in CYC- treated RMD patients 
who receive CYC monthly by intravenous administration. 
Acknowledging this lack of data on oral CYC–treated patients, it 
is  reasonable to consider gonadotropin- releasing hormone ago-
nist use for these patients. Theoretically, gonadotropin- releasing 
hormone agonist co- therapy may not be necessary for patients 
receiving the lower cumulative CYC dose in the Euro- Lupus 
regimen (49). Expense including insurance coverage issues and 
difficulty coordinating administration (preferred timing is 10–14 
days prior to CYC administration) may impact the ability to 
administer gonadotropin- releasing hormone agonist for the first 
CYC infusion, especially in the setting of urgent need for therapy.
Fertility preservation in men with RMD treated with 
CYC. CYC may cause infertility and long-term gonadal damage in 
treated men. Options for fertility preservation should be presented 
to male patients in whom CYC therapy is required.
We conditionally recommend against testosterone 
co-therapy in men with RMD receiving CYC, as it does 
not preserve fertility in men undergoing chemotherapy for 
malignancy (57).
Because sperm cryopreservation prior to treatment 
preserves a man’s ability to conceive a healthy child, we 
strongly suggest sperm cryopreservation as good practice 
for CYC-treated men who desire it.
We acknowledge the difficulty of coordinating sperm banking 
when CYC therapy is urgently indicated. Because CYC causes 
the most damage to the postmeiosis spermatids and sperm 
developing during therapy have the highest degree of genetic 
damage (58), sperm should be collected prior to CYC treatment. 
If sperm is collected after CYC treatment, urologists recommend 
waiting a minimum of 3 months after completion of therapy (59).
Menopause and hormone replacement therapy
Supplementary Appendix 7, Table D (http://onlin elibr ary.
wiley.com/doi/10.1002/acr.24130/ abstract) presents formal rec-
ommendations regarding menopause and HRT with strength of 
supporting evidence. Detailed justifications for strong and condi-
tional recommendations are shown in Supplementary Appendix 9 
(http://onlin elibr ary.wiley.com/doi/10.1002/acr.24130/ abstract). 
Figure 3 details the HRT decision- making process. In this guide-
line, postmenopausal women include women with surgically 
induced menopause.
Current population recommendations (60–62) suggest lim-
iting HRT use in healthy postmenopausal women and using 
the lowest dose that alleviates symptoms for the minimum time 
necessary. Studies of long- term HRT show that risks, including 
stroke and breast cancer, outweigh benefits (63). Risks of HRT 
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depend on the type, dose, route of administration, duration of use, 
and timing of initiation. Benefit- risk balance is most favorable for 
severe vasomotor symptoms in women ≤60 years old or within 10 
years of menopause onset (61).
Vasomotor symptoms, as defined by the North American 
Menopause Society, include hot flashes and night sweats. Hot 
flashes are recurrent, transient episodes of flushing, perspiration, 
and a sensation ranging from warmth to intense heat on the upper 
body and face, sometimes followed by chills. Night sweats are 
hot flashes that occur with perspiration during sleep (64). General 
contraindications to use of HRT include history of breast cancer, 
coronary heart disease, previous venous thromboembolic event 
or stroke, or active liver disease.
We strongly suggest as good practice the use of HRT 
in postmenopausal women with RMD without SLE or pos-
itive aPL who have severe vasomotor symptoms, have no 
contraindications, and desire treatment with HRT.
SLE patients. Use of HRT in symptomatic postmenopausal 
SLE patients may raise concerns regarding increased risk of flare 
and/or thrombosis; however, HRT use in aPL-negative women 
with quiescent SLE may be considered.
In SLE patients without positive aPL who desire HRT 
due to severe vasomotor symptoms and have no contrain-
dications, we conditionally recommend HRT treatment.
Moderate- quality direct evidence supports use of oral HRT in 
aPL- negative women with SLE who have stable low- level disease 
activity and no contraindication to use (65–68), although no stud-
ies have directly addressed use of HRT in patients with moderate- 
to- high disease activity. The recommendation is conditional 
because there was a small increase in risk of mild- to- moderate 
(but not severe) lupus flares with use of oral HRT in the Safety of 
Estrogens in Lupus Erythematosus National Assessment study 
(65), and because the studies did not include women with active 
disease.
aPL- positive patients. Estrogen use in aPL-positive 
patients should be avoided due to the potential increased risk of 
thrombosis. Data are limited, however, for many clinical situations, 
and specific recommendations vary in strength for this reason.
In women with asymptomatic aPL, we conditionally 
recommend against treating with HRT.
We strongly recommend against use of HRT in women 
with obstetric and/or thrombotic APS.
We conditionally recommend against HRT use in 
patients with APS who are receiving anticoagulation treat-
ment and in patients with APS who are currently negative 
for aPL.
We conditionally recommend consideration of HRT, if 
desired, in women who have a history of positive aPL but 
are currently testing negative for aPL and have no history 
of clinical APS.
Figure 3. Recommendations and good practice statements (GPS) for hormone replacement therapy (HRT) use in postmenopausal women 
with rheumatic and musculoskeletal disease (RMD). SLE = systemic lupus erythematosus; aPL = antiphospholipid antibody (persistent 
moderate- to- high–titer anticardiolipin or anti–β2- glycoprotein I antibody or persistent positive lupus anticoagulant); APS = antiphospholipid 
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Risk of VTE may be increased with HRT use in the general 
population (69,70). Types of estrogen and progestin and route of 
administration (71–74) affect risk. In the Women’s Health Initia-
tive study, VTE risk with oral estrogen- progestin increased 2- fold 
over placebo (70), and oral HRT in patients with factor V Leiden 
or prothrombin G20210A mutations increases VTE risk 25- fold 
compared to mutation- free women not receiving HRT (75,76). In 
contrast, recent studies show that transdermal estrogen does not 
increase VTE risk in healthy women (71,74), even those with pro-
thrombotic mutations or high body mass index (75,77). No stud-
ies, however, have specifically assessed thrombosis risk with oral 
or transdermal HRT in women with aPL.
Direct evidence regarding thrombosis risk with HRT in SLE 
patients with or without aPL is low, as studies have addressed risk 
of flare in SLE but not thrombosis, and some studies excluded 
patients with prior thrombosis (65,67). In one study 106 SLE 
patients, regardless of aPL status but excluding those with recent 
thrombosis, were randomized to receive oral estrogen- progestin 
HRT or placebo. Approximately one- third of the patients in each 
group had some degree of positivity for aPL (level unreported) 
(78). During 24 months of follow- up 3 thrombotic events occurred 
in the HRT group and 1 in the placebo group, a nonsignificant 
difference.
Available evidence supports the use, when indicated and 
desired, of HRT in RMD patients without aPL, including those 
with SLE (65). Given the demonstrated lower VTE risk with trans-
dermal administration as opposed to oral estrogen- progestin 
preparations even in women at increased prothrombotic risk 
(77), it may be reasonable to consider transdermal estrogen as 
initial therapy.
Pregnancy: general assessment, counseling, and 
management
Obstetrics- gynecology or maternal- fetal medicine specialists 
necessarily assume primary medical management of pregnancy 
in a woman with RMD. An understanding of basic pregnancy 
 physiology is helpful for rheumatologists to identify and treat active 
disease during pregnancy and coordinate care with obstetric 
 providers.
Pregnancy changes may impact manifestations of RMD. 
Pregnancy- related increased intravascular volume may worsen 
already abnormal cardiac or renal function. The expected 50% 
increase in glomerular filtration rate during pregnancy may worsen 
preexisting stable proteinuria. Pregnancy- induced hypercoag-
ulability increases RMD- associated thrombosis risk. The cal-
cium demand of fetal bone development and breastfeeding may 
worsen maternal osteoporosis. In addition, normal pregnancy 
symptoms such as malar erythema, chloasma gravidarum, ane-
mia, elevated erythrocyte sedimentation, and diffuse arthralgias 
may falsely mimic symptoms of active RMD. Pregnancy- induced 
hypertension syndromes (preeclampsia) may be confused with 
lupus nephritis, scleroderma renal crisis, or vasculitis flare. HELLP 
syndrome (hemolysis, elevated liver enzymes, and low platelets) 
or eclampsia may resemble severe disease flare. Distinguishing 
among these syndromes requires the expertise of rheumatologists 
and obstetrics- gynecology or maternal- fetal medicine physicians 
working together.
Most information regarding pregnancy management in RMD 
comes from observational studies, primarily in patients with SLE 
and APS. There have been very few controlled trials. Data about 
pregnancies in rare rheumatic diseases usually derive from small 
case series. For these reasons, many recommendations are condi-
tional, supported by collective experience of the Voting Panel mem-
bers and patient input. Supplementary Appendix 7, Table E (http://
onlin elibr ary.wiley.com/doi/10.1002/acr.24130/ abstract) presents 
formal recommendations regarding pregnancy in patients with 
RMD with strength of supporting evidence. Detailed justifications 
for strong and conditional recommendations are shown in Supple-
mentary Appendix 11 (http://onlin elibr ary.wiley.com/doi/10.1002/
acr.24130/ abstract). Figure 4 details the  pregnancy management 
process in patients with RMD. Supplementary Appendix 10 (http://
onlin elibr ary.wiley.com/doi/10.1002/acr.24130/ abstract) provides 
assessment and management suggestions for specific RMDs.
As standard good practice, we strongly suggest coun-
seling women with RMD who are considering pregnancy 
regarding the improved maternal and fetal outcomes (based 
on many studies) associated with entering pregnancy 
with quiescent/low activity disease (75,77,79–98). As addi-
tional good practice, we suggest maintaining concurrent 
care with specialists in obstetrics-gynecology, mater-
nal-fetal medicine, neonatology, and other specialists as 
 appropriate.
Patient participants expressed a strong desire that their 
physicians discuss family planning “early and often,” including 
before planning of pregnancy. Discussion with patients should 
include information on medications and impact of disease activ-
ity, autoantibodies, and organ system abnormalities on maternal 
and fetal health. In rare situations with significant disease- related 
damage, such as pulmonary arterial hypertension, renal dys-
function, heart failure, or other severe organ damage, pregnancy 
may be contraindicated due to high risk of maternal morbidity 
and mortality.
In women with RMD planning pregnancy who are 
receiving medication that is incompatible with preg-
nancy, we strongly recommend switching to a pregnancy- 
compatible medication and observing for sufficient time to 
assess efficacy and tolerability of the new medication.
There are no data to support a specific period of time for 
observation with pregnancy- compatible medications. Timing will 
vary depending on individual clinical factors; in clinical practice this 
is usually a minimum of several months.
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In women with RMD who are currently pregnant and 
have active disease that requires medical therapy, we 
strongly recommend initiating or continuing a pregnancy- 
compatible steroid-sparing medication, as both active RMD 
and continuous high-dose glucocorticoid treatment have 
potential for maternal and fetal harm (99).
Pre- pregnancy or early pregnancy laboratory testing for rele-
vant autoantibodies is recommended. Ascertaining anti- Ro/SSA, 
anti- La/SSB, and aPL status improves counseling regarding preg-
nancy and fetal risk.
We strongly recommend testing for anti-Ro/SSA and 
anti-La/SSB once before or early in pregnancy in women with 
SLE or SLE-like disorders, Sjögren’s syndrome, systemic 
sclerosis, and rheumatoid arthritis. Given the relative persis-
tence and unchanged titers of these antibodies, we strongly 
recommend against repeating the test during pregnancy.
Patients with scleroderma renal crisis. Most disease- 
specific recommendations for RMD pregnancy management 
focus on presence of underlying SLE or positive aPL. One aspect 
of disease in systemic sclerosis, however, is of particular impor-
tance during pregnancy: the development of scleroderma renal 
crisis. While effective medications are usually contraindicated dur-
ing pregnancy due to risk of adverse fetal effects, they should be 
considered in this unusual and life-threatening circumstance.
We strongly recommend use of angiotensin-converting 
enzyme inhibitor or angiotensin receptor blockade ther-
apy to treat active scleroderma renal crisis in pregnancy, 
because the risk of maternal or fetal death with untreated 
disease is higher than the risk associated with use of these 
medications during pregnancy.
While scleroderma renal crisis is rare in pregnancy (an esti-
mated 2% of scleroderma pregnancies), it can easily be confused 
Figure  4. Recommendations and good practice statements (GPS) for pregnancy counseling, assessment, and management in women 
with rheumatic and musculoskeletal disease (RMD). SLE = systemic lupus erythematosus; HCQ = hydroxychloroquine; NLE = neonatal lupus 
erythematosus; aPL = antiphospholipid antibody (persistent moderate- to- high–titer anticardiolipin or anti–β2- glycoprotein I antibody or persistent 
positive lupus anticoagulant); APS = antiphospholipid syndrome (obstetric and/or thrombotic); obstetric APS (OB APS) = patients meeting 
laboratory criteria for APS and having prior consistent pregnancy complications (≥3 consecutive losses prior to 10 weeks’ gestation, fetal loss at 
or after 10 weeks’ gestation, or delivery at <34 weeks due to preeclampsia, intrauterine growth restriction, or fetal distress) and with no history 
of thrombosis; thrombotic APS = patients meeting laboratory criteria for APS and having a prior thrombotic event (arterial or venous), regardless 
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with preeclampsia. Angiotensin- converting enzyme inhibitors can 
be renal- protective and life saving (100); however, they are contrain-
dicated in the second and third trimesters of pregnancy because of 
potential oligohydramnios or permanent fetal renal damage (101), 
and should be considered only for active scleroderma renal crisis.
SLE patients. Supplementary Appendix 7, Table E (http://
onlin elibr ary.wiley.com/doi/10.1002/acr.24130/ abstract) presents 
formal recommendations for SLE pregnancy management, with 
strength of supporting evidence. Detailed justifications for strong 
and conditional recommendations are shown in  Supplementary 
Appendix 11 (http://onlin elibr ary.wiley.com/doi/10.1002/acr.24130/ 
abstract).
In women with SLE who are considering pregnancy 
or are pregnant, we strongly recommend testing for LAC, 
aCL, and anti-β2GPI antibodies once before or early in 
pregnancy, and against repeating these tests during 
 pregnancy.
We recommend that all women with SLE take hydroxy-
chloroquine (HCQ) during pregnancy if possible. If a patient 
is already taking HCQ, we strongly recommend continuing 
it during pregnancy; if she is not taking HCQ, we condition-
ally recommend starting it if there is no contraindication.
Many studies support maternal and pregnancy benefit of HCQ 
and low risk for mother and fetus (84,102–111). Potential contrain-
dications include allergy, adverse side effects, or intolerance.
We conditionally recommend treating SLE patients 
with low-dose aspirin (81 or 100 mg daily), beginning in the 
first trimester.
The American College of Obstetricians and Gynecologists and 
US Protective Health Task Force recommend aspirin 81 mg daily 
as prophylaxis in all patients at high risk for preeclampsia (97,112–
117). Treatment with low- dose aspirin during pregnancy to prevent 
or delay the onset of gestational hypertensive disease is recom-
mended for those with SLE or APS because of their increased risk 
and may be considered for women with other RMD diagnoses 
depending on individual clinical risk factors. Some investigators 
have used doses of aspirin up to 150 mg daily, but both the Amer-
ican College of Obstetricians and Gynecologists and the U.S. Pre-
ventive Services Task Force note that there is a lack of appropriate 
comparative studies to show the superiority of doses >100 mg 
per day. Low- dose aspirin is not thought to complicate anesthesia 
or delivery (112); however, a decision regarding discontinuation 
prior to delivery should be made by the obstetrician- gynecologist 
and anesthesiologist according to the patient’s specific clinical 
situation.
Because active disease affects maternal and preg-
nancy outcome, we strongly suggest, as good practice, 
monitoring SLE disease activity with clinical history, exami-
nation, and laboratory tests at least once per trimester.
Abnormalities in the complete blood cell count, differential 
cell count, urinalysis results and urinary protein:creatinine ratio, 
or anti- DNA, C3, or C4 levels may indicate possible SLE flare 
and/or preeclampsia despite absence of clinical symptoms. 
 Frequency of laboratory monitoring and rheumatology follow- 
 up may vary with an individual patient’s clinical status and 
 medications.
Antiphospholipid antibody–positive patients. Preg-
nancies in patients with positive aPL or APS present specific 
challenges and may require additional monitoring and therapy. 
Supplementary Appendix 7, Table F (http://onlin elibr ary.wiley.com/
doi/10.1002/acr.24130/ abstract) presents formal recommenda-
tions, with strength of supporting evidence. Detailed justifications 
for strong and conditional recommendations are shown in Supple-
mentary Appendix 11 (http://onlin elibr ary.wiley.com/doi/10.1002/
acr.24130/ abstract).
Antiphospholipid antibody is a major risk factor for pregnancy 
loss and other adverse pregnancy outcomes, especially in SLE 
patients (118). Anti- β2GPI, aCL, and LAC should all be tested. 
Among aPLs, LAC conveys the greatest risk for adverse preg-
nancy outcome in women with or without SLE: the RR for adverse 
pregnancy outcome with LAC was 12.15 (95% CI 2.92–50.54, 
P = 0.0006) in the PROMISSE (Predictors of Pregnancy Outcome: 
Biomarkers in APL syndrome and SLE) study (118). Other inde-
pendent risk factors in aPL- positive women were younger age, 
history of thrombosis, and SLE.
Antiphospholipid antibody–positive patients without throm-
bosis or obstetric complications. Asymptomatic aPL-positive 
patients (those without pregnancy complications or history of 
thrombosis) are not generally treated with prophylactic therapy 
to prevent pregnancy loss. However, presence of aPL regardless 
of clinical history is considered a risk factor for development of 
preeclampsia.
In pregnant women with positive aPL who do not 
meet criteria for obstetric or thrombotic APS, we condi-
tionally recommend treating with prophylactic aspirin, 81 
or 100 mg daily, during pregnancy as preeclampsia proph-
ylaxis.
Treatment should begin early in pregnancy (before 16 weeks) 
and continue through delivery.
Patients with obstetric and thrombotic APS. Pregnancy 
increases the risk of thrombosis due to both hemostatic and 
anatomic factors. Patients who meet criteria for APS— whether 
obstetric or thrombotic—should receive therapy with heparin 
(usually LMWH) to improve pregnancy outcome and/or reduce 
risk of thrombosis.
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We strongly recommend combined low-dose aspirin 
and prophylactic-dose heparin (usually LMWH) for pa-
tients meeting criteria for OB APS (119–126).
This is based on evidence of moderate strength.
In women with OB APS, we further strongly recom-
mend treating with prophylactic-dose anticoagulation for 
6–12 weeks post partum (127).
In pregnant women with thrombotic APS, we strongly 
recommend treating with low-dose aspirin and therapeutic- 
dose heparin (usually LMWH) throughout pregnancy and 
post partum.
We conditionally recommend against using the combi-
nation of prophylactic-dose heparin and low-dose aspirin 
therapy for patients with positive aPL who do not meet cri-
teria for OB APS.
We appreciate and stress, however, that benefit in individual 
high- risk circumstances, such as triple- positive aPL or strongly 
positive LAC results, advanced maternal age, or IVF pregnancy, 
may outweigh risks of this therapy, and decisions should be made 
with discussion between physician and patient, weighing potential 
risks and benefits.
Other therapies for refractory OB APS. Despite improved 
outcomes with standard therapy with low-dose aspirin and 
prophylactic heparin/LMWH, additional treatments are needed 
for patients who do not respond to standard therapy. Intrave-
nous immunoglobuin, low-dose prednisone, increased dose of 
heparin/LMWH, and HCQ have all been suggested as additional 
or alternative treatments.
We conditionally recommend against treatment with 
intravenous immunoglobulin or an increased LMWH dose, 
as these have not been demonstrably helpful in cases of 
pregnancy loss despite standard therapy with low-dose 
aspirin and prophylactic heparin or LMWH.
Prophylactic- dose heparin and aspirin therapy for OB APS 
improves likelihood of live birth, but not necessarily full- term birth. 
Pregnancy loss occurs, despite treatment, in 25% of OB APS 
pregnancies. There are no data demonstrating improved out-
comes with a higher dose of heparin, and only anecdotal data 
support the use of intravenous immunoglobulin.
We strongly recommend against adding prednisone to 
prophylactic-dose heparin or LMWH and low-dose aspirin in 
patients in whom standard therapy has been unsuccessful, 
since there are no controlled studies demonstrating a benefit.
We acknowledge, however, that this recommendation is 
based on a lack of compelling data rather than data showing no 
clear benefit, and also that potential risk with this therapy is likely 
to be strongly affected by daily dosage, with higher doses impart-
ing greater risk of side effects.
We conditionally recommend the addition of HCQ to 
prophylactic-dose heparin or LMWH and low-dose aspirin 
therapy for patients with primary APS.
Recent small studies of APS pregnancies suggest that HCQ 
may decrease complications (111).
In pregnant women with positive aPL who do not meet 
criteria for APS and do not have another indication for the 
drug (such as SLE), we conditionally recommend against 
treating with prophylactic HCQ.
As with any unproven treatment, this therapy may be consid-
ered in specific circumstances, depending on a patient’s values 
and preferences and after a discussion about risks and benefits.
Anti- Ro/SSA and/or anti- La/SSB antibodies in preg-
nancy. Neonatal lupus erythematosus (NLE) describes sev-
eral fetal and infant manifestations caused by or associated 
with maternal anti- Ro/SSA (commonly) and anti- La/SSB auto-
antibodies. While isolated anti- La/SSB rarely imposes risk, when 
combined with anti- Ro/SSA, La/SSB antibodies may increase 
fetal risk (128). Prospective studies of infants born to women with 
 anti- Ro/SSA and/or anti- La/SSB antibodies show that ~10% 
develop an NLE rash, 20% transient cytopenias, and 30% mild 
transient transaminitis (estimates vary widely between reports). 
These complications are short- lived and spontaneously resolve as 
the child’s maternal antibodies disappear (129).
Complete (third- degree) heart block (CHB) occurs in ~2% of 
pregnancies of women with anti- Ro/SSA and/or anti- La/SSB anti-
bodies who have not had a prior infant with NLE, and in 13–18% 
of pregnancies of women with a prior infant who had either cuta-
neous or cardiac NLE (130). Low- titer antibodies are probably not 
associated with the same risk of CHB as higher titers (131). CHB 
rarely occurs after week 26. It is irreversible, and management 
transfers to pediatric cardiologists. Approximately 20% of children 
with CHB die in utero or in the first year of life; more than half will 
need a pacemaker (128).
Supplementary Appendix 7, Table G (http://onlin elibr ary.
wiley.com/doi/10.1002/acr.24130/ abstract) presents formal rec-
ommendations regarding pregnancy in women with anti- Ro/SSA 
and/or anti- La/SSB antibodies, with strength of supporting evi-
dence. Detailed justifications for strong and conditional recom-
mendations are shown in Supplementary Appendix 11 (http://
onlin elibr ary.wiley.com/doi/10.1002/acr.24130/ abstract).
In pregnant women with anti-Ro/SSA and/or anti-La/
SSB antibodies but no history of an infant with CHB or 
NLE, we conditionally recommend serial fetal echocar-
diography (less frequent than weekly; interval not deter-
mined) starting between 16 and 18 weeks and continuing 
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through week 26. For women with a prior infant with CHB 
or other NLE we conditionally recommend fetal echocar-
diography weekly, starting at week 16–18 and continuing 
through week 26.
Recommendations regarding monitoring for and treatment of 
CHB in women with anti- Ro/SSA and/or anti- La/SSB are all con-
ditional. Given the rarity of CHB, large case series are not available; 
most studies are retrospective and not randomized. An argument 
against screening includes the risk of identification and treatment 
of artifacts that do not impact offspring health, thus exposing both 
fetus and mother to long- term side effects of dexamethasone; this 
risk must be balanced against the potentially devastating impact 
of CHB. All discussions should acknowledge the limited data and 
consider the patient’s values and preferences.
We conditionally recommend treating all women who 
are positive for anti-Ro/SSA and/or anti-La/SSB antibodies 
with HCQ during pregnancy.
This is based on early and limited data and the low risk pro-
file of HCQ. Retrospective studies demonstrate that in pregnant 
women with a prior child with cardiac NLE who take HCQ, there is 
a lower risk of the current fetus developing CHB (132).
For pregnant women with anti-Ro/SSA and/or anti-La/
SSB antibodies and fetal first- or second-degree heart 
block shown on echocardiography, we conditionally recom-
mend treatment with oral dexamethasone 4 mg daily. If CHB 
 (without other cardiac inflammation) is present, we condi-
tionally recommend against treating with dexamethasone.
Fluorinated glucocorticoids, such as dexamethasone and 
betamethasone, cross the placenta; low- to- moderate–dose 
nonfluorinated glucocorticoids, such as prednisone and pred-
nisolone, are largely metabolized before they reach the fetus. 
Whether dexamethasone given for fetal first- or second- degree 
heart block changes outcome is a matter of controversy. 
Treatment should be limited to several weeks, depending on 
response, because of the risk of irreversible fetal and maternal 
toxicity. Whether dexamethasone improves long- term survival 
for a fetus with CHB is controversial (133,134), but recent analy-
ses do not support its use (135).
Medication use
Paternal medication use. Supplementary Appendix 7, Table 
H (http://onlin elibr ary.wiley.com/doi/10.1002/acr.24130/ abstract) 
presents best practice statements and recommendations regard-
ing paternal medication use in men with RMD, with strength of 
supporting evidence. Detailed justifications for strong and condi-
tional recommendations are shown in Supplementary Appendix 
12 (http://onlin elibr ary.wiley.com/doi/10.1002/acr.24130/ abstract). 
Table 2 summarizes recommendations for paternal medication use.
Medication issues differ between men with RMD who are 
planning to father a pregnancy and those whose sexual partner 
is pregnant. Pre- conception, the concerns are potential effects on 
male fertility and medication- associated teratogenicity. There are 
few published data addressing these potential effects of medica-
tions for RMD. A decision to stop a medication must be weighed 
against the impact it may have on paternal disease activity.
When the man’s partner is pregnant, the concern is whether 
his medication is present in seminal fluid and can transfer through 
vaginal mucosa, cross the placenta, and be teratogenic. In fact, 
post- conception exposure of the embryo or fetus is likely minimal, 
Table 2. Recommendations regarding medication use for men with rheumatic and musculoskeletal disease who are 
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as seminal concentrations of medications and volumes  transferred 
are small (136). There are no reports of post- conception terato-
genesis attributable to medications taken by a man with RMD. 
When a man’s sexual partner is pregnant, reassurance regarding 
low risk associated with his RMD treatment is generally warranted.
In the absence of adequate data regarding paternal exposure 
for most medications used for RMD, we developed recommen-
dation statements when 1) at least some data on paternal expo-
sure were available, 2) accumulated clinical experience of paternal 
exposure could guide the recommendation, or 3) there were no 
data on paternal exposure, but maternal exposure demonstrates 
teratogenicity. We do not present recommendations for new med-
ications with no available class- level or drug- specific data.
We strongly recommend against use of CYC and tha-
lidomide in men prior to attempting conception.
Paternal use of CYC may impair spermatogenesis or be 
mutagenic for DNA (137) and should be discontinued 3 months 
prior to attempting conception. Thalidomide is detectable in 
seminal fluid and is strongly teratogenic when given to pregnant 
women (138,139), and should be discontinued at least 1 month 
prior to attempting conception. The remaining medications are 
recommended either strongly or conditionally for continuation 
during peri- and post- conception periods.
In men with RMD who are planning to father a preg-
nancy, we strongly recommend continuation of HCQ, 
azathioprine, 6-mercaptopurine, colchicine, and tumor 
necrosis factor inhibitors (140–142).
In men with RMD who are planning to father a preg-
nancy, we conditionally recommend, based on a smaller 
body of evidence, continuing treatment with MTX, MMF, 
leflunomide, sulfasalazine, calcineurin inhibitors, and non-
steroidal antiinflammatory drugs (NSAIDs) (142–149). 
Although the drug label suggests discontinuation of MTX 
before attempting pregnancy, data show no evidence for 
mutagenesis or teratogenicity (143–145).
Although sulfasalazine may affect sperm count and quality, 
there are no data suggesting teratogenicity (146,150), and we con-
ditionally recommend its continuation. If conception does not occur, 
semen analysis should be considered.
We conditionally recommend continuation of anakinra 
and rituximab based on limited data (151,152).
Maternal medication use. Supplementary Appendix 
7, Tables I (conventional rheumatology medications), J (biologic 
rheumatology medications), and K (glucocorticoids) (http://onlin e 
libr ary.wiley.com/doi/10.1002/acr.24130/ abstract) present formal 
best practice statements and recommendations regarding mater-
nal medication use in patients with RMD, with strength of sup-
porting evidence. Detailed justifications for strong and conditional 
recommendations are shown in Supplementary Appendix 12  
(http://onlin elibr ary.wiley.com/doi/10.1002/acr.24130/ abstract). 
Table  3 summarizes recommendations for maternal medication 
use.
As standard good practice, we suggest discussing 
medications well before the patient attempts to conceive; 
we also suggest discussing pregnancy plans prior to initi-
ating treatment with medications that may affect gonadal 
function, such as CYC.
There are no published data regarding specific timing for 
medication discussion, which will vary according to the individ-
ual clinical situation, but in general we suggest adequate time 
to allow for appropriate medication changes and demonstration 
of tolerability and disease stability, usually a minimum of several 
months.
MTX, MMF, CYC, and thalidomide are known terato-
gens. We strongly recommend discontinuation of these 
within 3 months prior to conception (153–156).
Data regarding timing of discontinuation are conflicting and 
do not permit more specific recommendations. However, discon-
tinuation within 1 menstrual cycle would represent the minimum, 
and 3 months the most common, period for discontinuation. 
In addition to concerns about teratogenicity, it is optimal to 
allow adequate time for observation of disease stability without 
 medication.
For women treated with leflunomide, we strongly rec-
ommend cholestyramine washout if there are detectable 
serum levels of metabolite prior to or as soon as preg-
nancy is confirmed. Once metabolite is not detectable in 
the serum, the risks of pregnancy loss and birth defects are 
not elevated (157,158).
We conditionally recommend treatment with CYC for 
life-threatening conditions in the second or third trimester (86).
When potentially teratogenic medications are dis-
continued prior to pregnancy, we strongly recommend 
a period of observation without medication or transition 
to  pregnancy-compatible medications to ensure disease 
stability (as discussed above). In women with inadvertent 
exposure to teratogenic medications we strongly suggest 
immediate referral to a maternal-fetal medicine specialist, 
pregnancy medication specialist, or genetics counselor as 
standard good practice.
We strongly recommend HCQ, azathioprine/6- 
mercaptopurine, colchicine, and sulfasalazine, medications 
commonly used for RMD, as compatible for use throughout 
pregnancy (104,106,159–161).
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We conditionally recommend calcineurin inhibitors 
(tacrolimus and cyclosporine) and NSAIDs as compatible 
for use during pregnancy (154).
We conditionally recommend discontinuation of 
NSAIDs pre-conception if the patient is having difficulty 
conceiving (and if disease control would not be compro-
mised), due to the possibility of NSAID-induced unruptured 
follicle syndrome, a cause of subfertility (162).
We strongly recommend against use of NSAIDs in the 
third trimester because of the risk of premature closure of 
the ductus arteriosus (163).
We conditionally recommend nonselective NSAIDs 
over cyclooxygenase 2–specific inhibitors in the first 2 tri-
mesters, due to lack of data on cyclooxygenase 2–specific 
inhibitors.
Nonfluorinated glucocorticoids should be used when 
needed, but substitution of steroid- sparing pregnancy- compatible 
immunosuppressive therapy is desirable when high- dose or pro-
longed use is required.
We conditionally recommend continuing low-dose 
glucocorticoid treatment (≤10 mg daily of prednisone 
or nonfluorinated equivalent) during pregnancy if clini-
cally indicated. We strongly recommend tapering higher 
doses of nonfluorinated glucocorticoids to <20 mg daily 
of prednisone, adding a pregnancy-compatible glucocor-
ticoid-sparing agent if necessary. Although there are only 
minimal data regarding prolonged treatment with low-dose 
glucocorticoids during pregnancy, we conditionally recom-
mend against routine administration of stress-dose gluco-
corticoids at the time of vaginal delivery, but conditionally 
do recommend such treatment for surgical (cesarean) 
delivery.
We conditionally recommend continuing tumor necro-
sis factor inhibitor therapy with infliximab, etanercept, 
adalimumab, or golimumab prior to and during pregnancy 
(164,165). The tumor necrosis factor inhibitor certolizumab 
does not contain an Fc chain and thus has minimal placen-
tal transfer (166). We strongly recommend continuation of 
certolizumab therapy prior to and during pregnancy.
Placental transfer and fetal exposure for most biologic ther-
apies vary with gestational stage. The majority of RMD biologic 
therapies contain an Fc IgG1 construct that does not cross into 
the fetal circulation in significant concentrations until the second 
trimester (167). Use of the tumor necrosis factor (TNF)  inhibitors 
that include an IgG1 Fc construct during the third trimester 
(infliximab, etanercept, adalimumab, and golimumab) results 
in high levels of placental transfer and significant drug levels in 
the neonate. A modest amount of evidence suggests that these 
TNF inhibitors cause no adverse effects, especially in the first tri-
mester. There was extensive Voting Panel discussion regarding 
if, and when, these medications should be discontinued prior to 
delivery. The Voting Panel agreed that if the patient’s disease is 
under good control, these medications may be discontinued in 
the third trimester. While there is a paucity of safety data, con-
tinuing TNF inhibitors through delivery if the patient’s disease 
is active can be considered, with the understanding that the 
neonate will have significant serum levels of drug for a period 
of time.
There are limited data on the compatibility of other biolog-
ics with pregnancy. Given that these agents likely do not cross 
the placenta until the second trimester, the panel conditionally 
recommends that non–TNF inhibitor IgG- based molecules are 
compatible in the periconception period but should be discon-
tinued during pregnancy (i.e. at the time of the first positive preg-
nancy test result).
We conditionally recommend continuing treatment 
with anakinra, belimumab, abatacept, tocilizumab, secuki-
numab, and ustekinumab while a woman is trying to con-
ceive, but discontinuing once she is found to be pregnant.
If disease cannot be controlled with medications considered 
compatible with pregnancy, the physician and patient should dis-
cuss and weigh the possible risks from these medications versus 
the risks of uncontrolled disease during pregnancy.
We conditionally recommend continuing treatment 
with rituximab while a woman is trying to conceive, and 
we conditionally recommend continuing rituximab during 
pregnancy if severe life- or organ-threatening maternal dis-
ease so warrants.
Dosing in the second half of pregnancy puts the fetus at high 
risk of having minimal B cells at delivery (168).
There is no available evidence regarding use or safety of the 
new small- molecule agents, tofacitinib, baricitinib, and apremilast, 
during pregnancy. The Voting Panel elected not to offer recom-
mendations regarding these drugs. It should be noted, however, 
that small molecules are likely to pass through the placenta.
Medication use during breastfeeding. The benefits of 
breastfeeding are numerous (169–175); the American Academy 
of Pediatrics recommends exclusive breastfeeding for the first 6 
months and continued breastfeeding until 1 year (9). Because 
women with RMD may experience disease flare post partum and 
require treatment, it is important to balance benefits of disease 
control with risk of infant exposure through breast milk.
Infant serum levels of drugs ingested by the mother depend 
on multiple variables and are a function of drug concentration in 
breast milk, quantity of breast milk ingested, and drug absorp-
tion through the infant’s gastrointestinal tract. Premature infants 
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Table 4. Reproductive health care in patients with RMD: concise recommendation summary*
Topic Recommendation Strength
Contraception
All RMD Contraception/pregnancy discussion early and regularly; choose contraception 
based on safety, efficacy, and patient preference 
GPS
Use barrier methods if unable to use other methods GPS
Use emergency contraception if necessary [6] Strong
Women receiving immunosuppressive medications: Use IUD if desired [7] Strong
Women at risk for osteoporosis: Avoid DMPA [10] Conditional
Women receiving MMF: Use IUD or 2 other methods together [11] Conditional
RMD without SLE or aPL: Use highly effective or effective methods† [1] Strong
Highly effective methods preferred to effective methods [1A] Conditional
SLE SLE with negative aPL and low/stable disease activity: Use highly effective or 
effective methods† [2]
Strong
Highly effective methods preferred to effective methods [2A] Conditional
Avoid transdermal estrogen- progestin patch [2B] Conditional
SLE with negative aPL and moderate- to- high disease activity: Use progestin- only 
contraceptives or IUD [2C]
Strong




All RMD Stable disease and negative aPL: Proceed with assisted reproductive technology:
IVF if pregnancy- compatible medications [24] Strong
Oocyte cryopreservation: Continue medications except CYC [28] Strong
Active disease: Defer assisted reproductive technology until disease is stable/
quiescent [27]
Strong
SLE Active SLE: Defer assisted reproductive technology until disease is stable/quiescent [27] Strong
Do not treat with prophylactic prednisone [29] Conditional
Positive aPL No prior thromboses or OB APS: Prophylactic heparin or LMWH [25A] Conditional
No prior thromboses but history of OB APS: Prophylactic heparin or LMWH [25A2] Strong
Prior thromboses: Therapeutic heparin or LMWH [26A] Strong
Fertility preservation Women: Use gonadotropin- releasing hormone agonist therapy during IV CYC 
treatment [31]
Conditional
Men: Sperm cryopreservation pre–CYC treatment GPS
Do not use gonadotropin- releasing hormone agonist therapy [35] Conditional
Menopause/hormone  
replacement therapy
All RMD RMD without SLE or aPL: Treat with hormone replacement therapy if indicated‡ GPS
SLE SLE and negative aPL: Treat with hormone replacement therapy if indicated‡ [79] Conditional
Positive aPL If no prior thrombosis or OB APS: Do not treat with hormone replacement therapy [80] Conditional
If current titers negative, treat with hormone replacement therapy if indicated‡ [83] Conditional
If prior thrombosis or OB APS and not receiving anticoagulation treatment: Do not 
treat with hormone replacement therapy [81]
Strong
If current titers negative, do not treat with hormone replacement therapy [83A] Conditional
If prior thrombosis or OB APS and receiving anticoagulation treatment: Do not treat 
with hormone replacement therapy [82]
Conditional
Pregnancy
All RMD Counseling: Outcomes improved with pregnancy planning, stable disease, 
compatible medications, and co- management by rheumatology and obstetrics- 
gynecology/maternal- fetal medicine
GPS
Pre- pregnancy: Change to pregnancy- compatible medication and observe for 
stability [42]
Strong
If active disease during pregnancy: Initiate pregnancy- compatible medication [54] Strong
If SLE or SLE- like disease, SS, SSc, or RA: Test once (early) for anti- Ro/SSA and anti- La/
SSB [60, 62]
Strong
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Topic Recommendation Strength
SLE SLE or SLE- like disease: Test once (early) for aPL (aCL, anti- β2GPI, LAC) [59, 61] Strong
Continue HCQ during pregnancy [57] Strong
If not taking HCQ, start HCQ during pregnancy if no contraindications [58] Conditional
Monitor laboratory values at least once per trimester GPS
Treat with low- dose aspirin starting in first trimester [56] Conditional
Positive aPL Positive aPL only: If no prior thrombosis or OB APS, treat with low- dose aspirin 
starting in first trimester [45]
Conditional
Do not treat with combination prophylactic heparin or LMWH/low- dose  
aspirin [46]
Conditional
Do not treat with HCQ [44A] Conditional
OB APS: If no thrombosis but meet OB APS criteria, treat with combination 
prophylactic heparin or LMWH/low- dose aspirin [48]
Strong
Do not treat with combination therapeutic heparin or LMWH/low- dose  
aspirin [49]
Conditional
Do not treat with addition of IVIG [50] Conditional
Do not treat with addition of prednisone [51] Strong
Treat with addition of HCQ for combination heparin/low- dose aspirin failure [44B] Conditional
Treat with prophylactic anticoagulation during post partum period [84] Strong
Thrombotic APS: If prior thrombosis (meeting or not meeting OB APS criteria), treat 
with therapeutic heparin or LMWH/low- dose aspirin [52]
Strong
Treat with addition of HCQ for therapeutic heparin or LMWH/low- dose aspirin 
therapy failure [44B]
Conditional 
Positive anti- Ro/SSA with or 
without anti- La/SSB
Treat with HCQ during pregnancy [69, 70] Conditional
If no prior history of neonatal lupus: Serial (interval uncertain) fetal echocardiography 
in weeks 16–26 [67]
Conditional
If prior history of neonatal lupus: Weekly fetal echocardiography in weeks  
16–26 [68]
Conditional
Abnormal fetal echocardiography: If first- or second- degree heart block, treat with 
dexamethasone 4 mg daily [71, 72]
Conditional




Paternal medication If planning to father a child: Discuss medication use including CYC GPS
Discontinue CYC and thalidomide [133, 139] Strong/conditional
Continue HCQ, AZA, infliximab, etanercept, adalimumab, golimumab, certolizumab, 
colchicine [90, 115, 143, 146, 149, 152, 155, 97]
Strong
Continue leflunomide, MMF, NSAIDs, sulfasalazine, cyclosporine, tacrolimus, 
anakinra, rituximab [108, 119, 85, 94, 126, 130, 159, 163]
Conditional
Maternal medication If planning pregnancy: Discuss medication use including CYC GPS
If pregnant and exposed to teratogenic medications: Discontinue immediately, 
pursue counseling
GPS
Discontinue NSAIDs if difficulty conceiving [86] Conditional
Avoid NSAIDs in third trimester [87] Strong
Use nonselective rather than COX- 2–specific NSAIDs [88] Conditional
Discontinue MTX, MMF, thalidomide, CYC prior to conception [102, 120, 140, 134] Strong
Use CYC for life- threatening disease only in second and third trimester [136] Conditional
Discontinue leflunomide 24 months prior to conception or check serum metabolite 
levels and treat with cholestyramine washout [109, 110]
Strong
Continue HCQ, sulfasalazine, AZA, colchicine [91, 95, 116, 98] Strong
Continue cyclosporine and tacrolimus [127, 131] Conditional
Continue certolizumab [156] Strong
Continue infliximab, etanercept, adalimumab, golimumab [144, 147, 150, 153] Conditional
Stop when pregnancy confirmed: rituximab, belimumab, anakinra, abatacept, 
tocilizumab, secukinumab, ustekinumab [164, 169, 160, 173, 177, 181, 185]
Conditional
Use rituximab for organ- or life- threatening disease during pregnancy [165] Conditional
No recommendations for tofacitinib, baricitinib, apremilast due to lack of data 
[189, 193, 197]
Continue regular low- dose prednisone [201] Conditional
Table 4.  (Cont’d)
 (Continued)
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or those with gastrointestinal disorders may absorb medication 
differently. Rheumatologists should collaborate with pediatricians 
when making recommendations (176). Levels of drug in breast 
milk are routinely expressed as the relative infant dose (infant 
dose mg/kg/day divided by maternal dose mg/kg/day) and are 
available in reference publications; a value of <10% is considered 
safe.
Supplementary Appendix 7, Table L (http://onlin elibr ary.
wiley.com/doi/10.1002/acr.24130/ abstract) presents formal best 
practice statements and recommendations for use of medica-
tions during breastfeeding, with strength of supporting evidence. 
Detailed justifications for strong and conditional recommendations 
are shown in Supplementary Appendix 12 (http://onlin elibr ary.
wiley.com/doi/10.1002/acr.24130/ abstract).
We suggest as standard good practice that women 
with RMD be encouraged to breastfeed if they so desire 
and are able to do so. In addition, we suggest that disease 
control be maintained with lactation-compatible medica-
tions and that individualized risks and benefits be reviewed 
with each patient.
Fortunately, many RMD medications may be initiated or con-
tinued during lactation.
We strongly recommend treatment with HCQ, col-
chicine, sulfasalazine, rituximab, and all TNF inhibitors as 
compatible with breastfeeding (177–181).
We also recommend prednisone <20 mg daily (or 
equivalent nonfluorinated glucocorticoid) as compatible 
with breastfeeding, but strongly recommend that with 
doses of prednisone ≥20 mg a day (or equivalent), women 
delay breastfeeding or discard breast milk accumulated in 
the 4 hours following glucocorticoid administration.
We conditionally recommend treatment with azathio-
prine/6-mercaptopurine, calcineurin inhibitors, NSAIDs and 
the non–TNF inhibitor biologic agents (anakinra, rituximab, 
belimumab, abatacept, tocilizumab, secukinumab, and 
ustekinumab) as compatible with breastfeeding (182–184).
We strongly recommend against use of CYC, lefluno-
mide, MMF, and thalidomide while breastfeeding. We condi-
tionally recommend against use of MTX while breastfeeding.
Despite minimal passage of MTX into breast milk, especially 
with once- weekly dosing, this medication may accumulate in neo-
natal tissues (185,186).
Topic Recommendation Strength
Taper high- dose prednisone with addition of pregnancy- compatible drug if needed 
[202]
Strong
Stress- dose steroid at delivery: do not treat for vaginal delivery, do treat for cesarean 
delivery [206, 207]
Conditional




HCQ, infliximab, etanercept, adalimumab, golimumab, certolizumab, rituximab [92, 
143, 146, 149, 152, 155]
Strong
NSAIDs, sulfasalazine, colchicine, AZA, cyclosporine, tacrolimus, anakinra, belimumab, 
abatacept, tocilizumab, secukinumab, ustekinumab [89, 96, 99, 117, 128, 132, 161, 
170, 174, 178, 182, 186]
Conditional
Prednisone or nonfluorinated steroid equivalent <20 mg daily [204] Strong
For prednisone ≥20 mg daily, discard breast milk obtained within 4 hours following 
medication [205]
Strong
Do not treat with leflunomide, MMF, CYC, thalidomide [113, 124, 137, 142] Strong
Do not treat with MTX [106] Conditional
* Recommendation numbers, shown in brackets, allow for cross- referencing with supplementary appendices. For more detailed/complete 
recommendations, see text or Supplementary Appendix 7 (on the Arthritis Care & Research web site at http://onlinelibrary.wiley.com/doi/10.1002/
acr.24130/abstract). RMD = rheumatic and musculoskeletal disease; GPS = good practice statement; MMF = mycophenolate mofetil (and 
mycophenolic acid); SLE = systemic lupus erythematosus; aPL = antiphospholipid antibody, meeting laboratory criteria for antiphospholipid 
syndrome (APS) (Supplementary Appendix 8, http://onlinelibrary.wiley.com/doi/10.1002/acr.24130/ abstract); IVF = in vitro fertilization; CYC = 
cyclophosphamide; OB APS = APS meeting laboratory criteria and clinical obstetric criteria (Supplementary Appendix 8); LMWH = low molecular 
weight heparin; IV = intravenous; SS = Sjögren’s syndrome; SSc = systemic sclerosis; RA = rheumatoid arthritis; ACE inhibitor = angiotensin- 
converting enzyme inhibitor; ARB = angiotensin receptor blocker; aCL = anticardiolipin antibody; anti- β2GPI = anti–β2- glycoprotein I; LAC = 
lupus anticoagulant; HCQ = hydroxychloroquine; IVIG = IV immunoglobulin; AZA = azathioprine (and 5- fluorouracil); NSAIDs = nonsteroidal 
antiinflammatory drugs; COX- 2 = cyclooxygenase 2; MTX = methotrexate. 
† Highly effective contraceptives are long- acting reversible contraceptives including progestin or copper intrauterine device (IUD) and 
progestin implant. Effective contraceptives are estrogen- progestin contraceptives (oral, patch, or vaginal ring) and progestin- only (oral, depot 
medroxyprogesterone acetate [DMPA]). 
‡ General indication for hormone replacement therapy: Current recommendations suggest limiting hormone replacement therapy use in 
healthy postmenopausal women and using the lowest dose that alleviates symptoms for the minimum time necessary. Benefit- risk balance is 
most favorable for severe vasomotor symptoms in women <60 years old or within 10 years of menopause onset (ref. 61). 
Table 4.  (Cont’d)
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The Voting Panel declined to vote on the compatibility of new 
small- molecule agents regarding use during breastfeeding due 
to absence of data. In theory, however, these medications may 
transfer into breast milk because of their low molecular weights.
DISCUSSION
Patients’ reproductive health concerns are relevant for all 
practicing rheumatologists. Issues regarding contraception, fertil-
ity, pregnancy, lactation, and the offspring’s health affect almost 
every patient across all RMD diagnoses. The importance of this 
area is highlighted by recent publications that have addressed key 
elements of reproductive health for some or all RMD patients. The 
European League Against Rheumatism (EULAR) published rec-
ommendations regarding women’s health issues in patients with 
SLE and APS (187), and both EULAR (with points to consider) and 
the British Society for Rheumatology/British Health Professionals 
in Rheumatology (with guideline recommendations) addressed 
use of medications before, during, and after RMD pregnancy 
(188–190). Here, we address broad reproductive health concerns 
as well as medication use surrounding pregnancy for all RMD 
patients, with special attention, when indicated, for patients with 
specific disorders such as SLE or APS.
Even with the wide spectrum of reproductive issues 
addressed here (Table 4), this project has important limitations. 
This guideline was developed, and the literature review con-
ducted, in the adult population. An important future step will be 
to consider these issues among adolescents, as counseling and 
care for these patients may differ.
Another important limitation is the inability to include rec-
ommendations for uncommon but important clinical situations. 
Although our mandate was broad, our task was to derive and 
support our recommendations with available evidence, but many 
uncommon clinical scenarios have little published data. One such 
situation that reflects an ongoing research need is the challenge 
of reproductive health issues specific to transgender individuals, 
especially regarding hormonal therapies.
A relatively rare but important scenario is the therapeutic 
termination of pregnancy in patients with life- threatening disease 
damage or flare. Pregnancy in patients with preexisting severe 
organ damage carries profound maternal risk. Pulmonary arterial 
hypertension is associated with a particularly high risk of maternal 
mortality, estimated at up to 20% even with aggressive therapy 
(191). Other high- risk scenarios include severe renal insufficiency, 
cardiomyopathy, or valvular dysfunction. Severe autoimmune dis-
ease flare occurring during pregnancy—including diffuse alveolar 
hemorrhage, active nephritis or vasculitis, or central nervous sys-
tem inflammation—also carries high risk for maternal morbidity 
and mortality (55,192–194). In these and other high- risk situa-
tions, the option of therapeutic termination of pregnancy may be 
lifesaving and should be discussed with the patient (195). Deci-
sions regarding pregnancy termination in the setting of teratogenic 
medication exposure will depend on the specific medication, tim-
ing of exposure, and the patient’s assessment of the available 
data; counseling by expert professionals such as maternal- fetal 
medicine or genetics specialists regarding degree of risk based 
on specific circumstances is suggested in these cases.
We provide data- derived recommendations for common clin-
ical reproductive health decisions including recent advances in this 
area and emphasize the need for early involvement of the rheu-
matologist in reproductive health discussions involving patients 
with RMD, for instance, the importance of effective contracep-
tion. Almost half of pregnancies in the US are unplanned (196). 
In RMD patients unplanned pregnancies carry greater risk than 
do planned pregnancies in periods of low disease activity treated 
with compatible medications. Whether considering pregnancy or 
not, patients should know maternal and fetal risks, including fetal 
exposure to teratogenic medications and their safest and most 
effective contraception options.
Asking a patient about desire for pregnancy early and period-
ically (not only during perceived periods of change) and acknowl-
edging her personal risk factors will ensure open dialog. New 
information supports a shift from the paradigm of discon tinuing all 
RMD medications except prednisone, since pregnancy- compatible 
steroid- sparing disease- modifying antirheumatic drugs and biologic 
agents pose fewer short- and long- term risks to mother and infant. 
With adequate planning, treatment, and monitoring, most women 
with RMD can have successful pregnancies. Recent data indicate 
compatibility of many rheumatology medications both with lacta-
tion and with paternal use. The rheumatologist’s familiarity with drug 
safety during these periods is important to maintain disease control 
and minimize mother and infant risk.
Fertility and postmenopausal issues are not uncommon in 
RMD patients. Recommendations regarding ART reflect a grow-
ing demand among patients with RMD for fertility therapies. 
Oocyte freezing is now widely available (197). Attention to dis-
ease activity and aPL status and discussion with reproductive 
endocrinology and infertility specialists will optimize safety. For 
patients undergoing CYC therapy, the greatest challenge is to 
consider preservation of gonadal function and to initiate protec-
tive treatment protocols. HRT is another issue of importance for 
postmenopausal RMD patients. Severe vasomotor symptoms 
may be debilitating and if affected patients do not have aPL, HRT 
may improve quality of life.
The strength of evidence on reproductive health topics in 
RMD patients is moderate at best, and usually low, very low, 
or nonexistent for many topics of interest. Identification of areas 
with weak evidence highlights research priorities. One need is 
to establish the long- term safety profile of highly effective con-
traceptives in RMD patients with and without aPL. Although 
low- dose aspirin for preeclampsia prophylaxis in SLE and aPL 
patients is a low- risk intervention, its effectiveness is not known. 
Management of OB APS is one area with moderately strong 
evidence, but treatment for women with recurring adverse 
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 outcomes despite standard therapy is needed. Much in the field 
of prevention, screening, and management of NLE requires fur-
ther study. There are very limited data on RMD medication effects 
on fertility and teratogenicity in men with RMD. Because women 
with RMD who plan to conceive, are pregnant, or are lactating 
are usually excluded from clinical trials, large- scale data about 
medication use in these populations are also lacking. Pregnancy 
registries collect these data but suffer reporting bias and may 
not reflect the racial and ethnic make- up of the patient popula-
tion. Given the difficulties of collecting clinical data, research that 
focuses on better understanding of placental and breast phys-
iology, as well as drug and antibody transport, may help inform 
decision- making.
With the development of this guideline, the ACR recognizes 
the key role of clinical rheumatologists not only in  managing 
 disease activity but also in understanding the interactions of 
RMDs and their therapies in the context of reproductive health. 
The most important goal of this guideline is to provide substance 
and direction for discussion between clinicians and patients. A 
second goal is to encourage development of close working 
relationships among rheumatologists, specialists in obstetrics- 
gynecology, maternal- fetal medicine, and reproductive endocri-
nology and infertility, and other involved clinicians. We present this 
guideline as a resource to share, discuss, and disseminate across 
specialties and patient groups.
ACKNOWLEDGMENTS
We thank Adegbenga Bankole, MD, Karen Costenbader, 
MD, MPH, and Michael Weisman, MD for serving on the Expert 
Panel. We thank Roger Levy, MD, PhD for participating in the 
initial guideline scoping meeting. We thank Liana Frankel, MD 
for leading the Patient Panel meeting, as well the patients who 
(along with authors Rachelle Crow- Hercher and C. Whitney 
White) participated in this meeting: Jenee Johnson, Kamanta 
Kettle, Nicole Lumpkin, Teona Osborne, Melissa Perry- Bell, 
Mera Ramkissoon, Zenethia Roberts, Kaci Jackson Sanderson, 
Paula Sosin, and Bene Williams. We thank the ACR staff, includ-
ing Regina Parker for assistance in organizing the face- to- face 
Patient Panel and Voting Panel meetings and coordinating the 
administrative aspects of the project and Robin Lane for assis-
tance in manuscript preparation. We thank Janet Waters for help 
in developing the literature search strategy and performing the lit-
erature search and updates, and Janet Joyce for peer- reviewing 
the literature search strategy.
AUTHOR CONTRIBUTIONS
All authors were involved in drafting the article or revising it critically 
for important intellectual content, and all authors approved the final version 
to be published. Dr. Sammaritano had full access to all of the data in the 
study and takes responsibility for the integrity of the data and the accuracy 
of the data analysis.
Study conception and design. Sammaritano, Bermas, Chakravarty, 
Chambers, Clowse, Lockshin, Marder, Kavanaugh, Simard, Somers, 
Steen, Yazdany, Turner, D’Anci.
Acquisition of data. Sammaritano, Bermas, Chakravarty, Chambers, 
Clowse, Lockshin, Marder, Laskin, Tedeschi, Barbhaiya, Bettendorf, Eudy, 
Jayatilleke, Shah, Sullivan, Tarter, Turgunbaev, D’Anci.
Analysis and interpretation of data. Sammaritano, Bermas, Chakravarty, 
Chambers, Clowse, Lockshin, Marder, Guyatt, Branch, Buyon, Christopher- 
Stine, Crow- Hercher, Cush, Druzin, Kavanaugh, Laskin, Plante, Salmon, 
Simard, Somers, Steen, Tedeschi, Vinet, White, Barbhaiya, Bettendorf, 
Eudy, Jayatilleke, Shah, Sullivan, Tarter, Birru Talabi, Turgunbaev, D’Anci.
REFERENCES
 1. Smyth A, Oliveira GH, Lahr BD, Bailey KR, Norby SM, Garovic VD. 
A systematic review and meta- analysis of pregnancy outcomes in 
patients with systemic lupus erythematosus and lupus nephritis. 
Clin J Am Soc Nephrol 2010;5:2060–8.
 2. Smith CJ, Förger F, Bandoli G, Chambers CD. Factors associat-
ed with preterm delivery among women with rheumatoid arthritis 
and women with juvenile idiopathic arthritis. Arthritis Care Res 
 (Hoboken) 2019;71:1019–27.
 3. Langen ES, Chakravarty EF, Liaquat M, El-Sayed YY, Druzin ML. 
High rate of preterm birth in pregnancies complicated by rheuma-
toid arthritis. Am J Perinatol 2014;31:9–13.
 4. Chakravarty EF, Nelson L, Krishnan E. Obstetric hospitalizations in 
the United States for women with systemic lupus erythematosus 
and rheumatoid arthritis. Arthritis Rheum 2006;54:899–907.
 5. Bharti B, Lee SJ, Lindsay SP, Wingard DL, Jones KL, Lemus H, 
et al. Disease severity and pregnancy outcomes in women with 
rheumatoid arthritis: results from the Organization of Teratology In-
formation Specialists Autoimmune Diseases in Pregnancy Project. 
J Rheumatol 2015;42:1376–82.
 6. Borella E, Lojacono A, Gatto M, Andreoli L, Taglietti M, Iaccarino L, 
et al. Predictors of maternal and fetal complications in SLE patients: 
a prospective study. Immunol Res 2014;60:170–6.
 7. Ruiz-Irastorza G, Lima F, Alves J, Khamashta MA, Simpson J, 
Hughes GR, et al. Increased rate of lupus flare during pregnancy 
and the puerperium: a prospective study of 78 pregnancies. Br J 
Rheumatol 1996;35:133–8.
 8. Barrett JH, Brennan P, Fiddler M, Silman AJ. Does rheumatoid 
arthritis remit during pregnancy and relapse postpartum? Results 
from a nationwide study in the United Kingdom performed pro-
spectively from late pregnancy. Arthritis Rheum 1999;42:1219–27.
 9. Section on Breastfeeding. Breastfeeding and the use of human 
milk. Pediatrics 2012;129:e827–41.
 10. Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera 
R, et al. International consensus statement on an update of the 
classification criteria for definite antiphospholipid syndrome (APS). 
J Thromb Haemost 2006;4:295–306.
 11. Schwarz EB, Manzi S. Risk of unintended pregnancy among 
 women with systemic lupus erythematosus. Arthritis Rheum 2008; 
59:863–6.
 12. Yazdany J, Trupin L, Kaiser R, Schmajuk G, Gillis JZ, Chakravarty 
E, et al. Contraceptive counseling and use among women with sys-
temic lupus erythematosus: a gap in health care quality? Arthritis 
Care Res (Hoboken) 2011;63:358–65.
 13. Østensen M, von Esebeck M, Villiger PM. Therapy with immu-
nosuppressive drugs and biological agents and use of con-
traception in patients with rheumatic disease. J Rheumatol 
2007;34:1266–9.
 14. Allen D, Hunter MS, Wood S, Beeson T. One Key Question®: 
first things first in reproductive health. Matern Child Health J 
2017;21:387–92.
SAMMARITANO ET AL 484       |
 15. Amy JJ, Tripathi V. Contraception for women: an evidence based 
overview. BMJ 2009;339:b2895.
 16. Winner B, Peipert JF, Zhao Q, Buckel C, Madden T, Allsworth JE, 
et al. Effectiveness of long- acting reversible contraception. N Engl J 
Med 2012;366:1998–2007.
 17. Committee on Gynecologic Practice Long-Acting Reversible Con-
traception Working Group. Committee opinion no. 642:  increasing 
access to contraceptive implants and intrauterine devices to 
 reduce unintended pregnancy. Obstet Gynecol 2015;126:e44–8.
 18. Curtis KM, Tepper NK, Jatlaoui TC, Berry-Bibee E, Horton LG, 
Zapata LB, et al. U.S. medical eligibility criteria for contraceptive 
use, 2016. MMWR Recomm Rep 2016;65:1–103.
 19. Petri M, Kim MY, Kalunian KC, Grossman J, Hahn BH,  Sammaritano 
LR, et al. Combined oral contraceptives in women with systemic lu-
pus erythematosus. N Engl J Med 2005;353:2550–8.
 20. Sánchez-Guerrero J, Uribe AG, Jiménez-Santana L, Mestanza- Peralta  
M, Lara-Reyes P, Seuc AH, et al. A trial of contraceptive methods 
in women with systemic lupus erythematosus. N Engl J Med 2005; 
353:2539–49.
 21. Julkunen HA, Kaaja R, Friman C. Contraceptive practice in women 
with systemic lupus erythematosus. Br J Rheumatol 1993;32:227–
30.
 22. Galzote RM, Rafie S, Teal R, Mody SK. Transdermal delivery of 
combined hormonal contraception: a review of the current litera-
ture. Int J Womens Health 2017;9:315–21.
 23. Van den Heuvel MW, van Bragt AJ, Alnabawy AK, Kaptein MC. 
Comparison of ethinylestradiol pharmacokinetics in three hormonal 
contraceptive formulations: the vaginal ring, the transdermal patch 
and an oral contraceptive. Contraception 2005;72:168–74.
 24. Stam-Slob MC, Lambalk CB, van de Ree MA. Contraceptive and 
hormonal treatment options for women with history of venous 
thromboembolism. BMJ 2015;351:h4847.
 25. ACOG Committee on Practice Bulletins-Gynecology. ACOG prac-
tice bulletin no. 73: use of hormonal contraception in women with 
coexisting medical conditions. Obstet Gynecol 2006;107:1453–72.
 26. World Health Organization Department of Reproductive Health. 
Medical eligibility criteria for contraceptive use. 5th ed. 2015.
 27. Mantha S, Karp R, Raghavan V, Terrin N, Bauer KA, Zwicker JI. As-
sessing the risk of venous thromboembolic events in  women taking 
progestin- only contraception: a meta- analysis. BMJ 2012;345:e4944.
 28. Conard J, Plu-Bureau G, Bahi N, Horellou MH, Pelissier C, 
 Thalabard JC. Progestogen- only contraception in women at high 
risk of venous thromboembolism. Contraception 2004;70:437–41.
 29. Le Moigne E, Tromeur C, Delluc A, Gouillou M, Alavi Z, Lacut K, 
et al. Risk of recurrent venous thromboembolism on progestin- only 
contraception: a cohort study. Haematologica 2016;101:e12–4.
 30. Pisoni CN, Cuadrado MJ, Khamashta MA, Hunt BJ. Treatment 
of menorrhagia associated with oral anticoagulation: efficacy and 
safety of the levonorgestrel releasing intrauterine device (Mirena 
coil). Lupus 2006;15:877–80.
 31. Van Vlijmen EF, Veeger NJ, Middeldorp S, Hamulyák K, Prins MH, 
Büller HR, et al. Thrombotic risk during oral contraceptive use and 
pregnancy in women with factor V Leiden or prothrombin mutation: 
a rational approach to contraception. Blood 2011;118:2055–61.
 32. Stringer EM, Kaseba C, Levy J, Sinkala M, Goldenberg RL, Chi BH, 
et al. A randomized trial of the intrauterine contraceptive device vs 
hormonal contraception in women who are infected with the  human 
immunodeficiency virus. Am J Obstet Gynecol 2007;197:144.e1–8.
 33. Krajewski CM, Geetha D, Gomez-Lobo V. Contraceptive options 
for women with a history of solid- organ transplantation. Transplan-
tation 2013;95:1183–6.
 34. Huguelet PS, Sheehan C, Spitzer RF, Scott S. Use of the levonorge-
strel 52- mg intrauterine system in adolescent and young adult  solid 
organ transplant recipients: a case series. Contraception 2017; 
95:378–81.
 35. Clark M, Sowers M, Levy B, Nichols S. Bone mineral density 
loss and recovery during 48 months in first- time users of depot 
medroxyprogesterone acetate. Fertil Steril 2006;86:1466–74.
 36. Welcome to the mycophenolate REMS (Risk Evaluation and Mitiga-
tion Strategy). URL: https ://www.mycop henol atere ms.com/.
 37. Cellcept (mycophenolate mofetil) prescribing information. San 
 Francisco (CA): 2019. Genentech; 2019. URL: gene.com/download/ 
pdf/cellcept_prescribing.pdf.
 38. Mycophenolate: updated recommendations for contraception for 
men and women. December 2017. URL: https ://www.ema.europa.
eu/en/news/mycop henol ate-updat ed-recom menda tions-contr 
acept ion-men-women .
 39. Bellver J, Pellicer A. Ovarian stimulation for ovulation induction and 
in vitro fertilization in patients with systemic lupus erythematosus 
and antiphospholipid syndrome. Fertil Steril 2009;92:1803–10.
 40. Huong DL, Wechsler B, Vauthier-Brouzes D, Duhaut P, Costedoat 
N, Lefebvre G, et al. Importance of planning ovulation induction 
therapy in systemic lupus erythematosus and antiphospholipid syn-
drome: a single center retrospective study of 21 cases and 114 
cycles. Semin Arthritis Rheum 2002;32:174–88.
 41. Orquevaux P, Masseau A, Le Guern V, Gayet V, Vauthier D, 
 Guettrot-Imbert G, et al. In vitro fertilization in 37 women with sys-
temic lupus erythematosus or antiphospholipid syndrome: a series 
of 97 procedures. J Rheumatol 2017;44:613–8.
 42. Guballa N, Sammaritano L, Schwartzman S, Buyon J, Lockshin 
MD. Ovulation induction and in vitro fertilization in systemic lupus 
erythematosus and antiphospholipid syndrome. Arthritis Rheum 
2000;43:550–6.
 43. Chan WS, Dixon ME. The “ART” of thromboembolism: a review of 
assisted reproductive technology and thromboembolic complica-
tions. Thromb Res 2008;121:713–26.
 44. Nelson SM, Greer IA. Artificial reproductive technology and the 
risk of venous thromboembolic disease. J Thromb Haemost 2006; 
4:1661–3.
 45. Chan WS. The ‘ART’ of thrombosis: a review of arterial and venous 
thrombosis in assisted reproductive technology. Curr Opin Obstet 
Gynecol 2009;21:207–18.
 46. Yinon Y, Pauzner R, Dulitzky M, Elizur SE, Dor J, Shulman A. 
Safety of IVF under anticoagulant therapy in patients at risk 
for thrombo- embolic events. Reprod Biomed Online 2006;12: 
354–8.
 47. Nelson SM. Venous thrombosis during assisted reproduction: novel 
risk reduction strategies. Thromb Res 2013;131 Suppl 1:S1–3.
 48. Mok CC, Lau CS, Wong RW. Risk factors for ovarian failure in pa-
tients with systemic lupus erythematosus receiving cyclophospha-
mide therapy. Arthritis Rheum 1998;41:831–7.
 49. Tamirou F, Husson SN, Gruson D, Debiève F, Lauwerys BR, 
 Houssiau FA. The Euro- Lupus low- dose intravenous cyclophos-
phamide regimen does not impact the ovarian reserve, as mea sured 
by serum levels of anti–Müllerian hormone. Arthritis Rheumatol 
2017;69:1267–71.
 50. Oktay K, Harvey BE, Partridge AH, Quinn GP, Reinecke J, Taylor 
HS, et al. Fertility preservation in patients with cancer: ASCO clinical 
practice guideline update. J Clin Oncol 2018;36:1994–2001.
 51. Moore HC, Unger JM, Phillips KA, Boyle F, Hitre E, Porter D, 
et al. Goserelin for ovarian protection during breast- cancer adjuvant 
chemotherapy. N Engl J Med 2015;372:923–32.
 52. Blumenfeld Z, Mischari O, Schultz N, Boulman N, Balbir-Gurman 
A. Gonadotropin releasing hormone agonists may minimize cyclo-
phosphamide associated gonadotoxicity in SLE and autoimmune 
diseases. Semin Arthritis Rheum 2011;41:346–52.
ACR GUIDELINE FOR MANAGEMENT OF REPRODUCTIVE HEALTH IN RMDs |      485
 53. Brunner HI, Silva CA, Reiff A, Higgins GC, Imundo L, Williams CB, 
et al. Randomized, double- blind, dose- escalation trial of triptorelin 
for ovary protection in childhood- onset systemic lupus erythemato-
sus. Arthritis Rheumatol 2015;67:1377–85.
 54. Koga T, Umeda M, Endo Y, Ishida M, Fujita Y, Tsuji S, et al. Effect 
of a gonadotropin- releasing hormone analog for ovarian function 
preservation after intravenous cyclophosphamide therapy in sys-
temic lupus erythematosus patients: a retrospective inception co-
hort study. Int J Rheum Dis 2018;21:1287–92.
 55. Pagnoux C, Le Guern V, Goffinet F, Diot E, Limal N, Pannier E, et al. 
Pregnancies in systemic necrotizing vasculitides: report on 12 women 
and their 20 pregnancies. Rheumatology (Oxford) 2011;50:953–61.
 56. Somers EC, Marder W, Christman GM, Ognenovski V, McCune 
WJ. Use of a gonadotropin- releasing hormone analog for pro-
tection against premature ovarian failure during cyclophos-
phamide therapy in women with severe lupus. Arthritis Rheum 
2005;52:2761–7.
 57. Soares PM, Borba EF, Bonfa E, Hallak J, Corrêa AL, Silva CA. 
Gonad evaluation in male systemic lupus erythematosus. Arthritis 
Rheum 2007;56:2352–61.
 58. Wyrobek AJ, Schmid TE, Marchetti F. Relative susceptibilities of 
male germ cells to genetic defects induced by cancer chemothera-
pies. J Natl Cancer Inst Monogr 2005;2005:31–5.
 59. Stahl PJ, Stember DS, Hsiao W, Schlegel PN. Indications and 
strategies for fertility preservation in men. Clin Obstet Gynecol 
2010;53:815–27.
 60. ACOG Practice Bulletin no. 141: management of menopausal 
symptoms. Obstet Gynecol 2014;123:202–16.
 61. The NAMS 2017 Hormone Therapy Position Statement Advisory 
Panel. The 2017 hormone therapy position statement of the North 
American Menopause Society. Menopause 2017;24:728–53.
 62. U.S. Preventive Services Task Force. Hormone therapy for the 
prevention of chronic conditions in postmenopausal women: rec-
ommendations from the U.S. Preventive Services Task Force. Ann 
Intern Med 2005;142:855–60.
 63. Beral V, Million Women Study Collaborators. Breast cancer and 
hormone- replacement therapy in the Million Women Study. Lancet 
2003;362:419–27.
 64. North American Menopause Society. The 2012 hormone therapy 
position statement of the North American Menopause Society. 
Menopause 2012;19:257–71.
 65. Buyon JP, Petri MA, Kim MY, Kalunian KC, Grossman J, Hahn BH, 
et al. The effect of combined estrogen and progesterone hormone 
replacement therapy on disease activity in systemic lupus erythe-
matosus: a randomized trial. Ann Intern Med 2005;142:953–62.
 66. Mok CC, Lau CS, Ho CT, Lee KW, Mok MY, Wong RW. Safety of 
hormonal replacement therapy in postmenopausal patients with 
systemic lupus erythematosus. Scand J Rheumatol 1998;27:342–6.
 67. Sánchez-Guerrero J, González-Pérez M, Durand-Carbajal M, 
Lara-Reyes P, Jiménez-Santana L, Romero-Díaz J, et al. Meno-
pause hormonal therapy in women with systemic lupus erythema-
tosus. Arthritis Rheum 2007;56:3070–9.
 68. Kreidstein S, Urowitz MB, Gladman DD, Gough J. Hormone re-
placement therapy in systemic lupus erythematosus. J Rheumatol 
1997;24:2149–52.
 69. Marjoribanks J, Farquhar C, Roberts H, Lethaby A, Lee J. Long- 
term hormone therapy for perimenopausal and postmenopausal 
women. Cochrane Database Syst Rev 2017;1:CD004143.
 70. Cushman M, Kuller LH, Prentice R, Rodabough RJ, Psaty BM, 
Stafford RS, et al. Estrogen plus progestin and risk of venous 
thrombosis. JAMA 2004;292:1573–80.
 71. Canonico M, Oger E, Plu-Bureau G, Conard J, Meyer G, Lévesque 
H, et al, for the Estrogen and Thromboembolism Risk (ESTHER) 
Study Group. Hormone therapy and venous thromboembolism 
among postmenopausal women—impact of the route of estrogen 
administration and progestogens: the ESTHER study. Circulation 
2007;20;115:840–5.
 72. Sweetland S, Beral V, Balkwill A, Liu B, Benson VS, Canonico M, 
et al. Venous thromboembolism risk in relation to use of different 
types of postmenopausal hormone therapy in a large prospective 
study. J Thromb Haemost 2012;10:2277–86.
 73. Smith NL, Heckbert SR, Lemaitre RN, Reiner AP, Lumley T, Weiss 
NS, et al. Esterified estrogens and conjugated equine estrogens 
and the risk of venous thrombosis. JAMA 2004;292:1581–7.
 74. Rovinski D, Ramos RB, Fighera TM, Casanova GK, Spritzer PM. 
Risk of venous thromboembolism events in postmenopausal wom-
en using oral versus non- oral hormone therapy: a systematic review 
and meta- analysis. Thromb Res 2018;168:83–95.
 75. Straczek C, Oger E, Yon de Jonage-Canonico MB, Plu-Bureau G, 
Conard J, Meyer G, et al, for the Estrogen and Thromboembolism 
Risk (ESTHER) Study Group. Prothrombotic mutations, hormone 
therapy, and venous thromboembolism among postmenopausal 
women: impact of the route of estrogen administration. Circulation 
2005;112:3495–500.
 76. Rosendaal FR, Vessey M, Rumley A, Daly E, Woodward M, 
 Helmerhorst FM, et al. Hormonal replacement therapy,  prothrombotic 
mutations and the risk of venous thrombosis. Br J Haematol 2002; 
116:851–4.
 77. Canonico M, Plu-Bureau G, Lowe GD, Scarabin PY. Hormone re-
placement therapy and risk of venous thromboembolism in post-
menopausal women: systematic review and meta- analysis. BMJ 
2008;336:1227–31.
 78. Cravioto MD, Durand-Carbajal M, Jiménez-Santana L, Lara-Reyes 
P, Seuc AH, Sánchez-Guerrero J. Efficacy of estrogen plus proges-
tin on menopausal symptoms in women with systemic lupus ery-
thematosus: a randomized, double- blind, controlled trial. Arthritis 
Care Res (Hoboken) 2011;63:1654–63.
 79. Gupta R, Deepanjali S, Kumar A, Dadhwal V, Agarwal SK,  Pandey 
RM, et al. A comparative study of pregnancy outcomes and 
menstrual irregularities in northern Indian patients with system-
ic lupus erythematosus and rheumatoid arthritis. Rheumatol Int 
2010;30:1581–5.
 80. Lockshin MD. Pregnancy does not cause systemic lupus erythe-
matosus to worsen. Arthritis Rheum 1989;32:665–70.
 81. Le Thi Huong D, Wechsler B, Piette JC, Bletry O, Godeau P. Preg-
nancy and its outcome in systemic lupus erythematosus. QJM 
1994;87:721–9.
 82. Hussein Aly EA, Mohamed Riyad R, Nabil Mokbel A. Pregnancy 
outcome in patients with systemic lupus erythematosus: a single 
center study in the High Risk Pregnancy unit. Middle East Fertil Soc 
J 2016;21:168–74.
 83. Mintz G, Niz J, Gutierrez G, Garcia-Alonso A, Karchmer S. 
Prospective study of pregnancy in systemic lupus erythema-
tosus: results of a multidisciplinary approach. J Rheumatol 
1986;13:732–9.
 84. Mokbel A, Geilan AM, AboElgheit S. Could women with sys-
temic lupus erythematosus (SLE) have successful pregnancy 
 outcomes? Prospective observational study. Egypt Rheumatologist 
2013;35:133–9.
 85. Mankee A, Petri M, Magder LS. Lupus anticoagulant, disease activ-
ity and low complement in the first trimester are predictive of preg-
nancy loss. Lupus Sci Med 2015;2:e000095.
 86. Tuin J, Sanders JS, de Joode AA, Stegeman CA. Pregnancy in 
women diagnosed with antineutrophil cytoplasmic antibody– 
associated vasculitis: outcome for the mother and the child. Arthri-
tis Care Res (Hoboken) 2012;64:539–45.
SAMMARITANO ET AL 486       |
 87. Whitelaw DA, Hall D, Kotze T. Pregnancy in systemic lupus erythe-
matosus: a retrospective study from a developing community. Clin 
Rheumatol 2008;27:577–80.
 88. Croft AP, Smith SW, Carr S, Youssouf S, Salama AD, Burns A, et al. 
Successful outcome of pregnancy in patients with anti- neutrophil 
cytoplasm antibody–associated small vessel vasculitis. Kidney Int 
2015;87:807–11.
 89. Tozman EC, Urowitz MB, Gladman DD. Systemic lupus erythema-
tosus and pregnancy. J Rheumatol 1980;7:624–32.
 90. Ku M, Guo S, Shang W, Li Q, Zeng R, Han M, et al. Pregnancy 
outcomes in Chinese patients with systemic lupus erythemato-
sus (SLE): a retrospective study of 109 pregnancies. PLoS One 
2016;11:e0159364.
 91. Kothari R, Digole A, Kamat S, Nandanwar YS, Gokhale Y. Repro-
ductive health in systemic lupus erythematosus, an experience 
from government hospital in western India. J Assoc Physicians In-
dia 2016;64:16–20.
 92. Skorpen CG, Lydersen S, Gilboe IM, Skomsvoll JF, Salvesen KÅ, 
Palm Ø, et al. Influence of disease activity and medications on off-
spring birth weight, pre- eclampsia and preterm birth in systemic 
lupus erythematosus: a population- based study. Ann Rheum Dis 
2018;77:264–9.
 93. Phansenee S, Sekararithi R, Jatavan P, Tongsong T. Pregnancy 
outcomes among women with systemic lupus erythematosus: a 
retrospective cohort study from Thailand. Lupus 2018;27:158–64.
 94. Rahman FZ, Rahman J, Al-Suleiman SA, Rahman MS. Preg-
nancy outcome in lupus nephropathy. Arch Gynecol Obstet 2005; 
271:222–6.
 95. Bobrie G, Liote F, Houillier P, Grünfeld JP, Jungers P. Pregnancy in lupus 
nephritis and related disorders. Am J Kidney Dis 1987;9:339–43.
 96. Jungers P, Dougados M, Pélissier C, Kuttenn F, Tron F, Lesavre P, 
et al. Lupus nephropathy and pregnancy: report of 104 cases in 36 
patients. Arch Intern Med 1982;142:771–6.
 97. Gaballa HA, El-Shahawy EE, Atta DS, Gerbash EF. Clinical and se-
rological risk factors of systemic lupus erythematosus outcomes 
during pregnancy. Egypt Rheumatologist 2012;34:159–65.
 98. Tedeschi SK, Massarotti E, Guan H, Fine A, Bermas BL, 
 Costenbader KH. Specific systemic lupus erythematosus disease 
manifestations in the six months prior to conception are associ-
ated with similar disease manifestations during pregnancy. Lupus 
2015;24:1283–92.
 99. Palmsten K, Rolland M, Hebert MF, Clowse ME, Schatz M, Xu R, 
et al. Patterns of prednisone use during pregnancy in women with 
rheumatoid arthritis: daily and cumulative dose. Pharmacoepidemi-
ol Drug Saf 2018;27:430–8.
 100. Zanatta E, Polito P, Favaro M, Larosa M, Marson P, Cozzi F, et al. 
Therapy of scleroderma renal crisis: state of the art. Autoimmun 
Rev 2018;17:882–9.
 101. Bullo M, Tschumi S, Bucher BS, Bianchetti MG, Simonetti GD. 
Pregnancy outcome following exposure to angiotensin- converting 
enzyme inhibitors or angiotensin receptor antagonists: a systematic 
review. Hypertension 2012;60:444–50.
 102. Liu EL, Liu Z, Zhou YX. Feasibility of hydroxychloroquine adjuvant 
therapy in pregnant women with systemic lupus erythematosus. 
Biomed Res 2018;29:980–3.
 103. Leroux M, Desveaux C, Parcevaux M, Julliac B, Gouyon JB, Dal-
lay D, et al. Impact of hydroxychloroquine on preterm delivery and 
intrauterine growth restriction in pregnant women with systemic 
lupus erythematosus: a descriptive cohort study. Lupus 2015;24: 
1384–91.
 104. Eudy AM, Siega-Riz AM, Engel SM, Franceschini N, Howard AG, 
Clowse ME, et al. Effect of pregnancy on disease flares in patients with 
systemic lupus erythematosus. Ann Rheum Dis 2018;77:855–60.
 105. Clowse ME, Magder L, Witter F, Petri M. Hydroxychloroquine in 
lupus pregnancy. Arthritis Rheum 2006;54:3640–7.
 106. Diav-Citrin O, Blyakhman S, Shechtman S, Ornoy A. Pregnancy out-
come following in utero exposure to hydroxychloroquine: a prospec-
tive comparative observational study. Reprod Toxicol 2013;39:58–62.
 107. Hwang JK, Park HK, Sung YK, Hoh JK, Lee HJ. Maternal out-
comes and follow- up of preterm and term neonates born to moth-
ers with systemic lupus erythematosus. J Matern Fetal Neonatal 
Med 2018;31:7–13.
 108. Kroese SJ, de Hair MJ, Limper M, Lely AT, van Laar JM, Derksen 
RH, et al. Hydroxychloroquine use in lupus patients during preg-
nancy is associated with longer pregnancy duration in preterm 
births. J Immunol Res 2017;2017:2810202.
 109. Georgiou PE, Politi EN, Katsimbri P, Sakka V, Drosos AA. Outcome 
of lupus pregnancy: a controlled study. Rheumatology (Oxford) 
2000;39:1014–9.
 110. Teh CL, Wong JS, Ngeh NK, Loh WL. Systemic lupus erythema-
tosus pregnancies: a case series from a tertiary, East Malaysian 
hospital. Lupus 2009;18:278–82.
 111. Ruffatti A, Tonello M, Hoxha A, Sciascia S, Cuadrado M,  Latino JO, 
et al. Effect of additional treatments combined with  conventional 
therapies in pregnant patients with high- risk antiphospholipid syn-
drome: a multicentre study. Thromb Haemost 2018;118:639–46.
 112. ACOG committee opinion no. 743: low- dose aspirin use during 
pregnancy. Obstet Gynecol 2018;132:e44–52.
 113. LeFevre ML, US Preventive Services Task Force. Low- dose aspirin 
use for the prevention of morbidity and mortality from preeclampsia: 
U.S. Preventive Services Task Force recommendation statement. 
Ann Intern Med 2014;161:819–26.
 114. Buyon JP, Kim MY, Guerra MM, Laskin CA, Petri M, Lockshin MD, 
et al. Predictors of pregnancy outcomes in patients with lupus: a 
cohort study. Ann Intern Med 2015;163:153–63.
 115. Abheiden CN, Blomjous BS, Kroese SJ, Bultink IE, Fritsch-Stork 
RD, Lely AT, et al. Low- molecular- weight heparin and aspirin use 
in relation to pregnancy outcome in women with systemic lupus 
erythematosus and antiphospholipid syndrome: a cohort study. Hy-
pertens Pregnancy 2017;36:8–15.
 116. Moroni G, Doria A, Giglio E, Imbasciati E, Tani C, Zen M, et al. 
Maternal outcome in pregnant women with lupus nephritis: a pro-
spective multicenter study. J Autoimmun 2016;74:194–200.
 117. Imbasciati E, Tincani A, Gregorini G, Doria A, Moroni G,  Cabiddu 
G, et al. Pregnancy in women with pre- existing lupus nephritis: 
predictors of fetal and maternal outcome. Nephrol Dial Transplant 
2009;24:519–25.
 118. Lockshin MD, Kim M, Laskin CA, Guerra M, Branch DW, Merrill J, 
et al. Prediction of adverse pregnancy outcome by the  presence of 
lupus anticoagulant, but not anticardiolipin antibody, in  patients with 
antiphospholipid antibodies. Arthritis Rheum 2012;64: 2311–8.
 119. Bao SH, Sheng SL, Liao H, Zhou Q, Frempong ST, Tu WY. Use of 
D- dimer measurement to guide anticoagulant treatment in recur-
rent pregnancy loss associated with antiphospholipid syndrome. 
Am J Reprod Immunol 2017;78:e12770.
 120. Farquharson RG, Quenby S, Greaves M. Antiphospholipid syn-
drome in pregnancy: a randomized, controlled trial of treatment. 
Obstet Gynecol 2002;100:408–13.
 121. Van Hoorn ME, Hague WM, van Pampus MG, Bezemer D, de Vries 
JI, for the FRUIT investigators. Low- molecular- weight heparin and 
aspirin in the prevention of recurrent early- onset pre- eclampsia in 
women with antiphospholipid antibodies: the FRUIT- RCT. Eur J Ob-
stet Gynecol Reprod Biol 2016;197:168–73.
 122. Naru T, Khan RS, Ali R. Pregnancy outcome in women with an-
tiphospholipid syndrome on low- dose aspirin and heparin: a retro-
spective study. East Mediterr Health J 2010;16:308–12.
ACR GUIDELINE FOR MANAGEMENT OF REPRODUCTIVE HEALTH IN RMDs |      487
 123. Goel N, Tuli A, Choudhry R. The role of aspirin versus aspirin and 
heparin in cases of recurrent abortions with raised anticardiolipin 
antibodies. Med Sci Monit 2006;12:CR132–6.
 124. Brewster JA, Shaw NJ, Farquharson RG. Neonatal and pediatric 
outcome of infants born to mothers with antiphospholipid syn-
drome. J Perinat Med 1999;27:183–7.
 125. Cohn DM, Goddijn M, Middeldorp S, Korevaar JC, Dawood F, 
Farquharson RG. Recurrent miscarriage and antiphospholipid an-
tibodies: prognosis of subsequent pregnancy. J Thromb Haemost 
2010;8:2208–13.
 126. Clark CA, Spitzer KA, Crowther MA, Nadler JN, Laskin MD, Waks 
JA, et al. Incidence of postpartum thrombosis and preterm delivery 
in women with antiphospholipid antibodies and recurrent pregnan-
cy loss. J Rheumatol 2007;34:992–6.
 127. ACOG practice bulletin no. 196: thromboembolism in pregnancy. 
Obstet Gynecol 2018;132:e1–17.
 128. Brito-Zerón P, Izmirly PM, Ramos-Casals M, Buyon JP, Khamashta 
MA. The clinical spectrum of autoimmune congenital heart block. 
Nat Rev Rheumatol 2015;11:301–12.
 129. Wahren-Herlenius M, Sonesson SE, Clowse ME. Neonatal lupus 
erythematosus. In: Wallace D, Hahn B, editors. Dubois’ lupus er-
ythematosus and related syndromes. 8th ed. Philadelphia: Saun-
ders; 2012. p. 464–72.
 130. Izmirly PM, Rivera TL, Buyon JP. Neonatal lupus syndromes. 
Rheum Dis Clin North Am 2007;33:267–85.
 131. Kan N, Silverman ED, Kingdom J, Dutil N, Laskin C, Jaeggi E. Serial 
echocardiography for immune- mediated heart disease in the fetus: 
results of a risk- based prospective surveillance strategy. Prenat 
 Diagn 2017;37:375–82.
 132. Izmirly PM, Costedoat-Chalumeau N, Pisoni CN, Khamashta MA, 
Kim MY, Saxena A, et al. Maternal use of hydroxychloroquine is 
associated with a reduced risk of recurrent anti- SSA/Ro- antibody–
associated cardiac manifestations of neonatal lupus. Circulation 
2012;126:76–82.
 133. Cuneo BF, Lee M, Roberson D, Niksch A, Ovadia M, Parilla BV, 
et al. A management strategy for fetal immune- mediated atrioven-
tricular block. J Matern Fetal Neonatal Med 2010;23:1400–5.
 134. Friedman DM, Kim MY, Copel JA, Llanos C, Davis C, Buyon JP. 
Prospective evaluation of fetuses with autoimmune- associated 
congenital heart block followed in the PR Interval and Dexametha-
sone Evaluation (PRIDE) study. Am J Cardiol 2009;103:1102–6.
 135. Izmirly PM, Saxena A, Sahl SK, Shah U, Friedman DM, Kim MY, 
et al. Assessment of fluorinated steroids to avert progression and 
mortality in anti- SSA/Ro- associated cardiac injury limited to the fe-
tal conduction system. Ann Rheum Dis 2016;75:1161–5.
 136. Colie CF. Male mediated teratogenesis. Reprod Toxicol 1993;7: 
3–9.
 137. Anderson D, Bishop JB, Garner RC, Ostrosky-Wegman P, Selby 
PB. Cyclophosphamide: review of its mutagenicity for an assess-
ment of potential germ cell risks. Mutat Res 1995;330:115–81.
 138. Brandenburg NA, Bwire R, Freeman J, Houn F, Sheehan P,  Zeldis 
JB. Effectiveness of risk evaluation and mitigation strategies 
(REMS) for lenalidomide and thalidomide: patient comprehension 
and knowledge retention. Drug Saf 2017;40:333–41.
 139. Teo SK, Harden JL, Burke AB, Noormohamed FH, Youle M, 
 Johnson MA, et al. Thalidomide is distributed into human semen 
after oral dosing. Drug Metab Dispos 2001;29:1355–7.
 140. Larsen MD, Friedman S, Magnussen B, Nørgård BM. Birth out-
comes in children fathered by men treated with anti- TNF- α agents 
before conception. Am J Gastroenterol 2016;111:1608–13.
 141. Nørgård BM, Magnussen B, Larsen MD, Friedman S. Reassuring 
results on birth outcomes in children fathered by men treated with 
azathioprine/6- mercaptopurine within 3 months before conception: 
a nationwide cohort study. Gut 2017;66:1761–6.
 142. Ben-Chetrit E, Berkun Y, Ben-Chetrit E, Ben-Chetrit A. The out-
come of pregnancy in the wives of men with familial Mediterrane-
an fever treated with colchicine. Semin Arthritis Rheum 2004;34: 
549–52.
 143. Weber-Schoendorfer C, Hoeltzenbein M, Wacker E, Meister R, 
Schaefer C. No evidence for an increased risk of adverse pregnan-
cy outcome after paternal low- dose methotrexate: an observational 
cohort study. Rheumatology (Oxford) 2014;53:757–63.
 144. Eck LK, Jensen TB, Mastrogiannis D, Torp-Pedersen A, Askaa B, 
Nielsen TK, et al. Risk of adverse pregnancy outcome after paternal 
exposure to methotrexate within 90 days before pregnancy. Obstet 
Gynecol 2017;129:707–14.
 145. Winter RW, Larsen MD, Magnussen B, Friedman S, Kammerlander 
H, Nørgård BM. Birth outcomes after preconception paternal ex-
posure to methotrexate: a nationwide cohort study. Reprod Toxicol 
2017;74:219–23.
 146. Wallenius M, Lie E, Daltveit AK, Salvesen KÅ, Skomsvoll JF, Kalstad 
S, et al. No excess risks in offspring with paternal preconception 
exposure to disease- modifying antirheumatic drugs. Arthritis Rheu-
matol 2015;67:296–301.
 147. Kieseier BC, Benamor M. Pregnancy outcomes following mater-
nal and paternal exposure to teriflunomide during treatment for 
relapsing- remitting multiple sclerosis. Neurol Ther 2014;3:133–8.
 148. Midtvedt K, Bergan S, Reisæter AV, Vikse BE, Åsberg A. Exposure 
to mycophenolate and fatherhood. Transplantation 2017;101: 
e214–7.
 149. Jones A, Clary MJ, McDermott E, Coscia LA, Constantinescu S, 
Moritz MJ, et al. Outcomes of pregnancies fathered by solid- organ 
transplant recipients exposed to mycophenolic acid products. Prog 
Transplant 2013;23:153–7.
 150. Sands K, Jansen R, Zaslau S, Greenwald D. The safety of thera-
peutic drugs in male inflammatory bowel disease patients wishing 
to conceive [review]. Aliment Pharmacol Ther 2015;41:821–34.
 151. Youngstein T, Hoffmann P, Gül A, Lane T, Williams R, Rowczenio DM, 
et al. International multi- centre study of pregnancy outcomes with 
interleukin- 1 inhibitors. Rheumatology (Oxford) 2017;56:2102–8.
 152. Ciron J, Audoin B, Bourre B, Brassat D, Durand-Dubief F,  Laplaud 
D, et al. Recommendations for the use of rituximab in neuromyelitis 
optica spectrum disorders. Rev Neurol (Paris) 2018;174:255–64.
 153. Feldkamp M, Carey JC. Clinical teratology counseling and consul-
tation case report: low dose methotrexate exposure in the early 
weeks of pregnancy. Teratology 1993;47:533–9.
 154. Kainz A, Harabacz I, Cowlrick IS, Gadgil SD, Hagiwara D. Review of 
the course and outcome of 100 pregnancies in 84 women treated 
with tacrolimus. Transplantation 2000;70:1718–21.
 155. Sifontis NM, Coscia LA, Constantinescu S, Lavelanet AF, Moritz 
MJ, Armenti VT. Pregnancy outcomes in solid organ transplant 
recipients with exposure to mycophenolate mofetil or sirolimus. 
Transplantation 2006;82:1698–702.
 156. Vargesson N. Thalidomide- induced teratogenesis: history and 
mechanisms. Birth Defects Res C Embryo Today 2015;105:140–56.
 157. Bérard A, Zhao JP, Shui I, Colilla S. Leflunomide use during preg-
nancy and the risk of adverse pregnancy outcomes. Ann Rheum 
Dis 2018;77:500–9.
 158. Weber-Schoendorfer C, Beck E, Tissen-Diabaté T, Schaefer C. 
 Leflunomide—a human teratogen? A still not answered question: 
an evaluation of the German Embryotox pharmacovigilance data-
base. Reprod Toxicol 2017;71:101–7.
 159. Connell W, Miller A. Treating inflammatory bowel disease during 
pregnancy: risks and safety of drug therapy. Drug Saf 1999;21: 
311–23.
 160. Indraratna PL, Virk S, Gurram D, Day RO. Use of colchicine in 
pregnancy: a systematic review and meta- analysis. Rheumatology 
 (Oxford) 2018;57:382–7.
SAMMARITANO ET AL 488       |
 161. Saavedra MÁ, Sánchez A, Morales S, Ángeles U, Jara LJ. 
 Azathioprine during pregnancy in systemic lupus erythematosus 
patients is not associated with poor fetal outcome. Clin Rheumatol 
2015;34:1211–6.
 162. Brouwer J, Hazes JM, Laven JS, Dolhain RJ. Fertility in women with 
rheumatoid arthritis: influence of disease activity and medication. 
Ann Rheum Dis 2015;74:1836–41.
 163. Koren G, Florescu A, Costei AM, Boskovic R, Moretti ME. Non-
steroidal antiinflammatory drugs during third trimester and the risk 
of premature closure of the ductus arteriosus: a meta- analysis. Ann 
Pharmacother 2006;40:824–9.
 164. Bröms G, Granath F, Ekbom A, Hellgren K, Pedersen L, Sørensen 
HT, et al. Low risk of birth defects for infants whose mothers are 
treated with anti- tumor necrosis factor agents during pregnancy. 
Clin Gastroenterol Hepatol 2016;14:234–41.
 165. Diav-Citrin O, Otcheretianski-Volodarsky A, Shechtman S, Ornoy 
A. Pregnancy outcome following gestational exposure to TNF- α- 
inhibitors: a prospective, comparative, observational study. Reprod 
Toxicol 2014;43:78–84.
 166. Mariette X, Förger F, Abraham B, Flynn AD, Moltó A, Flipo RM, et al. 
Lack of placental transfer of certolizumab pegol during pregnancy: 
results from CRIB, a prospective, postmarketing, pharmacokinetic 
study. Ann Rheum Dis 2018;77:228–33.
 167. Kane SV, Acquah LA. Placental transport of immunoglobulins: a 
clinical review for gastroenterologists who prescribe therapeutic 
monoclonal antibodies to women during conception and pregnan-
cy. Am J Gastroenterol 2009;104:228–33.
 168. Chakravarty EF, Murray ER, Kelman A, Farmer P. Pregnancy out-
comes after maternal exposure to rituximab. Blood 2011;117: 
1499–506.
 169. Sheard NF, Walker WA. The role of breast milk in the development 
of the gastrointestinal tract. Nutr Rev 1988;46:1–8.
 170. Hanson LA, Ahlstedt S, Andersson B, Carlsson B, Fällström SP, 
Mellander L, et al. Protective factors in milk and the development of 
the immune system. Pediatrics 1985;75:172–6.
 171. Ladomenou F, Moschandreas J, Kafatos A, Tselentis Y, Galanakis E. 
Protective effect of exclusive breastfeeding against infections during 
infancy: a prospective study. Arch Dis Child 2010;95:1004–8.
 172. Armstrong J, Reilly JJ. The prevalence of obesity and undernutrition 
in Scottish children: growth monitoring within the Child Health Sur-
veillance Programme. Scott Med J 2003;48:32–7.
 173. Davis MK, Savitz DA, Graubard BI. Infant feeding and childhood 
cancer. Lancet 1988;2:365–8.
 174. Horta BL, Loret de Mola C, Victora CG. Long- term conse quences 
of breastfeeding on cholesterol, obesity, systolic blood  pressure 
and  type 2 diabetes: a systematic review and meta- analysis 
 [review]. Acta Paediatr 2015;104:30–7.
 175. Schwarz EB, Ray RM, Stuebe AM, Allison MA, Ness RB, Freiberg 
MS, et al. Duration of lactation and risk factors for maternal cardio-
vascular disease. Obstet Gynecol 2009;113:974–82.
 176. Newton ER, Hale TW. Drugs in breast milk. Clin Obstet Gynecol 
2015;58:868–84.
 177. Motta M, Tincani A, Faden D, Zinzini E, Lojacono A, Marchesi A, 
et al. Follow- up of infants exposed to hydroxychloroquine given to 
mothers during pregnancy and lactation. J Perinatol 2005;25:86–9.
 178. Ben-Chetrit E, Scherrmann JM, Levy M. Colchicine in breast 
milk of patients with familial Mediterranean fever. Arthritis Rheum 
1996;39:1213–7.
 179. Bragnes Y, Boshuizen R, de Vries A, Lexberg Å, Østensen M. Low 
level of rituximab in human breast milk in a patient treated during 
lactation [letter]. Rheumatology (Oxford) 2017;56:1047–8.
 180. Berlin CM Jr, Yaffe SJ. Disposition of salicylazosulfapyridine (Azu-
lfidine) and metabolites in human breast milk. Dev Pharmacol Ther 
1980;1:31–9.
 181. Fritzsche J, Pilch A, Mury D, Schaefer C, Weber-Schoendorfer C. 
Infliximab and adalimumab use during breastfeeding [letter]. J Clin 
Gastroenterol 2012;46:718–9.
 182. Gardiner SJ, Gearry RB, Roberts RL, Zhang M, Barclay ML, Begg 
EJ. Comment: breast- feeding during maternal use of azathioprine. 
Ann Pharmacother 2007;41:719–20.
 183. Bramham K, Chusney G, Lee J, Lightstone L, Nelson-Piercy C. 
Breastfeeding and tacrolimus: serial monitoring in breast- fed and 
bottle- fed infants. Clin J Am Soc Nephrol 2013;8:563–7.
 184. Matro R, Martin CF, Wolf D, Shah SA, Mahadevan U. Exposure 
concentrations of infants breastfed by women receiving biologic 
therapies for inflammatory bowel diseases and effects of breast-
feeding on infections and development. Gastroenterology 2018; 
155:696–704.
 185. American Academy of Pediatrics Committee on Drugs. Transfer 
of drugs and other chemicals into human milk. Pediatrics 2001; 
108:776–89.
 186. Johns DG, Rutherford LD, Leighton PC, Vogel CL. Secretion 
of methotrexate into human milk. Am J Obstet Gynecol 1972; 
112:978–80.
 187. Andreoli L, Bertsias GK, Agmon-Levin N, Brown S, Cervera R, Cost-
edoat-Chalumeau N, et al. EULAR recommendations for women’s 
health and the management of family planning, assisted reproduc-
tion, pregnancy and menopause in patients with systemic lupus 
erythematosus and/or antiphospholipid syndrome. Ann Rheum Dis 
2017;76:476–85.
 188. Flint J, Panchal S, Hurrell A, van de Venne M, Gayed M, Schreiber 
K, et al. BSR and BHPR guideline on prescribing drugs in preg-
nancy and breastfeeding—part I: Standard and biologic disease 
modifying anti- rheumatic drugs and corticosteroids. Rheumatology 
(Oxford) 2016;55:1693–7.
 189. Flint J, Panchal S, Hurrell A, van de Venne M, Gayed M, Schreiber 
K, et al. BSR and BHPR guideline on prescribing drugs in preg-
nancy and breastfeeding—part II: analgesics and other drugs used 
in rheumatology practice. Rheumatology (Oxford) 2016;55:1698–
702.
 190. Götestam Skorpen C, Hoeltzenbein M, Tincani A, Fischer-Betz R, 
Elefant E, Chambers C, et al. The EULAR points to consider for use 
of antirheumatic drugs before pregnancy, and during pregnancy 
and lactation. Ann Rheum Dis 2016;75:795–810.
 191. Meng ML, Landau R, Viktorsdottir O, Banayan J, Grant T, 
Bateman B, et al. Pulmonary hypertension in pregnancy: a report 
of 49 cases at four tertiary North American sites. Obstet Gynecol 
2017;129:511–20.
 192. Sangle SR, Vounotrypidis P, Briley A, Nel L, Lutalo PM, Sanchez- 
Fernandez S, et al. Pregnancy outcome in patients with systemic vas-
culitis: a single- centre matched case- control study.  Rheumatology 
(Oxford) 2015;54:1582–6.
 193. Ritchie J, Smyth A, Tower C, Helbert M, Venning M, Garovic V. Ma-
ternal deaths in women with lupus nephritis: a review of published 
evidence. Lupus 2012;21:534–41.
 194. El-Sayed YY, Lu EJ, Genovese MC, Lambert RE, Chitkara U,  Druzin 
ML. Central nervous system lupus and pregnancy: 11- year experience 
at a single center. J Matern Fetal Neonatal Med 2002;12:99–103.
 195. Society for Maternal-Fetal Medicine (SMFM). Executive summa-
ry: Reproductive Services for Women at High Risk for Maternal 
 Mortality Workshop, February 11–12, 2019, Las Vegas, Nevada. 
Am J Obstet Gynecol 2019;221:B2–5.
 196. Finer LB, Zolna MR. Declines in unintended pregnancy in the United 
States, 2008–2011. N Engl J Med 2016;374:843–52.
 197. Practice Committees of American Society for Reproduc-
tive Medicine, Society for Assisted Reproductive Technolo-
gy. Mature oocyte cryopreservation: a guideline. Fertil Steril 
2013;99:37–43.
